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 Dengue fever is a mosquito-borne disease that is prevalent in tropical and 
subtropical regions of the world. In some severe cases, this disease leads to dengue 
hemorrhagic fever (DHF) or dengue shock syndrome (DSS), which may lead to loss 
of life. The WHO estimates more than fifty million cases of dengue fever occurring 
every year, hence there is a need for drug-discovery and vaccine development for 
dengue fever. The aim of this thesis is to identify and characterize three antiviral 
compounds, NITD448, NITD770 and U18666A, as novel anti-dengue compounds. 
 In the first study, a rational approach was used to create a library of small 
molecules. These compounds were structurally predicted to bind to the dengue 
envelope protein. A medium throughput assay measuring cell-cell fusion activity was 
developed to screen this library and this screening led to the identification of a novel 
small molecule compound (NITD448) which was validated to block dengue fusion 
and infection.  
 In the second study, a small molecule mevalonate pyrophosphate 
decarboxylase (MVD) inhibitor (NITD770) was tested for anti-viral activity in 
DENV. It exhibited a good anti-viral activity with a therapeutic window of more than 
100. Its anti-viral activity was also found to be specific against flaviviruses. However, 
subsequent studies confirmed that MVD was not the target of NITD770 and hence, 
there was a need to determine its mode of mechanism. During the studies to determine 
the mode of mechanism of NITD770, host lipid rafts (as suggested by chemogenomic 
profiling data) and cholesterol were confirmed not targeted by this compound. Gene 
sequencing of resistant viruses raised against the compound revealed that resistant 
mutations were within the NS5 RNA-dependent RNA polymerase (RdRp) coding 
region. When these mutations were introduced into wild type RdRp, an increased in 
IX 
 
polymerase activity was observed but these mutations did not rescue the suppression 
effect of NITD770, implying that these were compensatory mutations.  
 In the final study, the importance of host cholesterol to dengue infection was 
investigated using an amphiphile, U18666A.When two main sources of cholesterol in 
the host cell, i.e., extracellular cholesterol intake and cholesterol biosynthesis, were 
inhibited by U18666A, dengue infection was suppressed. Subsequent studies further 
showed that when extracellular cholesterol transport into host cell was arrested by 
U18666A, it resulted in inefficient trafficking of dengue viruses. Immuno-
flourescence studies revealed that these viruses were trapped in the host late 
endosomes, which were heavily loaded with the accumulated cholesterol, and unable 
to undergo fusion. This resulted in reduced infection. U18666A was also shown in 
this study to have a suppression effect on viral replication and further studies 
suggested that it could be caused by the reduction of host de-novo biosynthesis of 
cholesterol by this compound.  
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1.1. HISTORY OF DENGUE INFECTIONS 
Dengue fever (DF) is a mosquito-borne viral disease that affects humans. The 
disease is caused by a virus known as dengue virus (DENV). DENV was first 
successfully isolated from human patients in Hawaii (DENV-1) and New Guinea 
(DENV-2) in 1944, and subsequently in the Philippines (DENV-3 & DENV-4). 
Dengue fever can be caused by four distinct but related serotypes of dengue virus 
(DENV-1 to 4). It made its deadly presence known to the medical field in the 1950s 
when a severe form of dengue fever, Dengue Hemorrhagic Fever (DHF), surfaced 
during epidemics in the Philippines and Thailand. This disease is also known as 
“break-bone” fever, perhaps owing to the symptoms observed in DF patients, which 
include intense headaches and body aches. 
Dengue fever is classified as an emerging disease, with initially less than ten 
countries reporting to have DHF (prior to 1970), to more than hundred countries 
displaying cases of DHF. The World Health Organization (WHO) currently estimates 
more than fifty million cases of dengue fever every year. The escalating number of 
cases is a worrying issue as there is no cure to date. Tropical and sub-tropical climates 
are environments where dengue thrives and with the increasing global travelling, a 
spread in the disease is thought to be inevitable (Gubler 2002). Reports of epidemics 
in several countries are occurring more frequently in this century; often with more 
severity than ever displayed before. This is of particular concern to countries with 






1.2. BIOLOGY OF DENGUE VIRUS 
1.2.1.  Taxonomy of dengue virus  
 Dengue virus (DENV) belongs to the family of Flaviviridae that consists of  
three genera, flavivirus (e.g. dengue virus, West Nile virus, and yellow fever virus), 
hepacivirus (hepatitis C virus) and pestivirus (e.g. bovine viral diarrhea virus), as 
shown in figure 1. The detailed taxonomy and classification can be found at the 
International Committee on Taxonomy of Viruses website at 
http://www.ictvonline.org/virusTaxonomy.asp. This family of viruses is mostly 
arthropod-borne, with a complex transmission cycling between the vectors (mostly 
mosquitoes and ticks) and host vertebrates. There are two known transmission cycles 
for DENV: (i) human hosts and Aedes mosquitoes (mainly, Aedes Aegypti) and (ii) a 
sylvatic cycle involving non-human primates and Aedes mosquitoes (Gubler 1988; 












Figure 1-1: Whole genome phylogenetic tree of family Flaviviridae. This tree is 
reconstructed using maximum parsimony. Color coding for arcs is as follows: Red 
(Aedes borne Flaviviruses), Purple (Culex borne Flaviviruses), Blue (Tick borne 
Flaviviruses), Orange (No known vector Flaviviruses), Green (Pestiviruses), Cyan 
(Hepaciviruses) and Black (unassigned members of family Flaviviridae). 
Reprinted by permission from BioMed Central: [BMC Bioinformatics] (Kulkarni-
Kale U, Bhosle SG, Manjari GS, Joshi M, Bansode S, and Kolaskar AS. 2006. 
Curation of viral genomes: challenges, applications and the way forward. BMC 





1.2.2. Structure and genetic organization of dengue virus  
 Previous ultra-structural studies showed that dengue virus is a 50 nm 
icosahedral entity with a surprisingly smooth surface. DENV particle is made up of a 
RNA core that is encapsidated by nucleo-capsid, which is wrapped by a lipid bilayer 
membrane, followed by an organized outer protein shell (Zhang et al. 2003). 
The dengue genome (as shown in figure 2) is composed of a positive single stranded 
RNA of approximately 11 kb in size. It is organized into three structural viral proteins 
(capsid (C), pre-membrane (prM) and envelope (E)), and seven non-structural 
proteins essential for viral replication (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) 





Figure 1-2: Dengue virus genome: It is a polyprotein composed of three structural 
proteins (highlighted in green) and seven non-structural proteins (highlighted in blue).  
Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews 
Microbiology] (Whitehead S, Blaney J, Durbin A, and Murphy B. 2007. Prospects for 



















1.2.3. Viral infection cycle  
The infection cycle of DENV (as depicted in Figure 3) begins with the binding 
of DENV onto the host cell surface with a receptor, probably a low affinity but 
abundance receptor, such as DC-SIGN (Tassaneetrithep et al. 2003). The virus is then 
endocytosed into the cell via an unknown high affinity specific receptor (Lozach et al. 
2005). When encountering a change in pH within the acidic environment of the late 
endosome, protonation of the histidine residues of the viral envelope occurs (Mueller 
et al, 2008). This triggers the E protein to undergo major conformational changes 
which leads to the fusion of the viral membrane with host endosomal membrane. The 
fusion event releases the nucleocapsid, containing the genetic material, into the 
cytoplasm. Positive strand viral RNA is translated into a single polyprotein that is 
further processed into structural and non structural viral proteins by viral and host 
cellular proteases. Viral replication is initiated on the intercellular membranes near to 
the host endoplasmic reticulum (ER). Newly synthesized viral proteins are assembled, 
in the ER, into immature non-infectious virions. These immature virions are 
subsequently transported to the trans-Golgi apparatus for processing; resulting in the 



















Figure 1-3: Infection cycle of dengue virus in host cell. 
Reprinted from Host Cell. Cell Host & Microbe, 5(4), Fernandez-Garcia M-D, 
Mazzon M, Jacobs M, and Amara, A., Pathogenesis of Flavivirus Infections: Using 
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1.2.4. Viral proteins 
 Viral RNA is packaged inside the DENV capsid to forms the RNA core, 
known as nucleocapsid. This RNA core protects the viral genome before its delivery 
into the host cell cytoplasm for initiation of viral replication. After viral fusion, the 
viral capsid localizes to both cytoplasm and nuclease of the host cell. The reason for 
nuclear localization is still poorly understood. There were studies done suggesting the 
possible roles of capsid in (i) virus-induced apoptosis, (ii) viral assembly (Khromykh 
and Westaway 1996), (iii) viral morphogenesis (Samsa et al. 2009) and (iv) acting as 
an antagonist of an excocyst protein (hSec3p), which is a repressor of viral replication  
(Bhuvanakantham et al. 2009).  
 The membrane protein of DENV is initially presented as a pre-membrane 
form (prM). It acts as a shield covering the fusion peptides of DENV envelope 
protein, preventing it from premature fusion with the cellular membrane during the 
synthesis of new viral particles. During the final step of viral assembly (known as 
maturation), it is cleaved by a host protease, furin, with the “pr” peptide remains 
associated with the virion in the environment of the TGN. This association keeps the 
virus in a non-infectious state inside the cell. Upon exiting the cell, “pr” peptide 
dissociates from the virus, making the virion infectious. This primes the mature virion 
for fusion upon entry into acidic compartments of host cells. 
 DENV is an enveloped virus which contains a lipid bilayer that has 180 copies 
of E protein and M protein embedded in it. The E proteins are arranged in an 
icosahedral scaffold of 90 dimers (Kuhn et al. 2002). The fusion protein of DENV E 
protein is classified as a class II fusion protein, similar to those belonging to 
alphaviruses and flaviviruses. The E protein has three domains, domain I being the 
central domain, flanked by a dimerization domain (domain II) on one end and 
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immunoglobulin-like domain (domain III) on the other end (Mukhopadhyay et al. 
2005). The discovery of a hydrophobic pocket, occupied by a small detergent 
molecule, n-octyl-β-D-glucoside (βOG), near to the hinge region of the E protein, 
highlighted an attractive region for anti-viral targeting (details are to be further 
discussed in later section, see chapter 1.3.3). Other important roles of E proteins 
include receptor-mediated binding, neutralization and viral assembly (Chin et al. 
2007; Crill and Roehrig 2001; Hiramatsu et al. 1996; Stiasny et al. 2006) 
 The non-structural protein, NS1, exists in both soluble and insoluble forms 
(Winkler et al. 1989). During the replication event of DENV, NS1 is anchored to the 
intracellular membrane of the endoplasmic reticulum, mainly as homodimers (Falgout 
and Markoff 1995; Mackenzie et al. 1996), and is implicated to participate in viral 
replication. It is also found to be associated with the cell surface via a GPI-anchor and 
is capable of triggering signal transduction (Jacobs et al. 2000). The soluble form of 
NS1 circulates in the extra-cellular compartment in the form of a hexamer (Flamand 
et al. 1999). Soluble NS1 levels were found to be elevated in the blood serum of 
dengue fever patients during the acute phase of the disease (Young et al. 2000). It is 
believed that these circulating soluble NS1 hexamers could contribute to the 
pathogenesis of the disease by reacting with the host complement system, causing 
activation and the onset of host immune responses, leading to a vascular leakage 
(Avirutnan et al. 2006).  
 NS2B-NS3 complex of DENV is an excellent example of efficient fusion of 
various functional proteins into one protein which allows sequential processes to take 
place in close association. NS3 has the viral protease at its N-terminal end that cleaves 
the viral polyprotein together with host proteases. At the C-terminal end of NS3 is the 
viral helicase with a RNA-stimulated nucleoside triphosphatase to provide the energy 
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to unwind viral RNA replication intermediates during amplification of viral RNA. 
NS2B is a co-factor of NS3, acting as a putative anchor for NS3 protease to the host 
membrane in order to allow efficient proteolytic activity. Other non-enzymatic 
functions of flaviviral NS3 have been suggested, such as substrate recognition 
(capped viral RNA) (Luo et al. 2008; Patkar and Kuhn 2008) and the recruitment of 
fatty acid synthase to the site of replication for fatty acid biosynthesis, which is 
necessary for viral replication (Heaton et al. 2010).  
 NS5 is another non-structural protein of DENV with multi-enzymatic 
properties. At the N-terminus of NS5 is the viral methyltransferase, which is involved 
in the methylation of the N7 and 2‟-O positions of viral RNA cap. RNA capping 
stabilizes viral mRNA for efficient translation (Furuichi and Shatkin 2000; Wengler 
1993). The RNA-dependent RNA polymerase (RdRp) domain is found in the C-
terminal region of NS5 and is responsible for the amplification of viral RNA 
(Ackermann and Padmanabhan 2001; Tan et al. 1996; Yap et al. 2007). NS5 also has 
a non-enzymatic function in modulating the host responses by binding to STAT2, 
resulting in the suppression of interferon signalling involved in anti-viral response in 
host (Ashour et al. 2009; Mazzon et al. 2009). 
 NS2A, NS4A and NS4B are non-structural proteins that are generally believed 
to possess non-enzymatic functions. All have been shown to antagonize IFN 
signalling with NS4B having the most potent anti-IFN activity. The function of NS4A 
is still relatively elusive, although that it is known to be localized to the replication 
site, and is shown to induce the formation of membranous structures similar to those 
observed in infected cells (Miller et al. 2007). NS4B has been implicated in enhancing 
the overall helicase activity of NS3 by causing the dissociation of NS3 from single-
stranded RNA (Umareddy et al. 2006). 
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1.3. PATHOGENESIS OF DENGUE INFECTION 
1.3.1. The course of dengue infection 
         There is a usual incubation period of one week, upon bitten by an infected 
mosquito, before viremia is detected in the infected human. Commonly observed in 
dengue fever (DF) patient is the sudden onset of illness which has the following 
phases: febrile, critical and recovery (Dengue guidelines by WHO, 2009 report). In 
the febrile period, patient encounters an abrupt onset of high fever lasting more than a 
week and other symptoms such as red-spots in the skin, myalgia, retro-orbital pain, 
muscle and joints pains and headache. In the case of dengue fever, the acute febrile 
period usually comes and goes away within a week of illness, with patients recovering 
from the disease. However, in some unfortunate cases, Dengue Hemorrhagic Fever 
(DHF) or Dengue Shock Syndrome (DSS) may occur whereby patient‟s health 
deteriorates further and experiences serious complications, progressing into what is 
known as the critical period which lasts from 24 to 48 hours. 
During the critical period, patient‟s platelet count starts to drop critically, 
together with a rapid rise in haematocrit, due to plasma leakage (Epidemiological 
News Bulletin by Tan Tock Seng Hospital, 2005). Other clinical symptoms observed 
in DHF patients include thrombocytopenia and hemorrhagic manifestation. DSS 
occurs when there is a critical volume of plasma lost through increased in capillary 
permeability. Fluid resuscitation is required to treat the resulting hypovolemic shock 
as patient may die within 12-36 hours if there is no immediate treatment of this 
complication (Martina et al. 2009). If the patient recovers from the critical phase, 
platelet count will gradually return to normal with a restoration of the general well-
being of the patient‟s health. 
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1.3.2. Cross reactive T cells and deregulation of cytokine production 
The cellular immune response consists of heterogeneous populations of 
antigen-specific T cells (CD4 & CD8) that effectively eradicate invading pathogens. 
Although these virus-specific T cells clear viruses, these T cells can also exacerbate 
tissue injury and induce pathogenesis of the diseases (Cannon et al. 1988; Klavinskis 
et al. 1989; Kurane and Ennis 1992). In the case of DF, the severity of the disease is 
believed to be attributed from the amplification of cytokine release caused by 
secondary infection occurring in the presence of memory T cells (Rothman and Ennis 
1999).  
DENV-specific CD4+ and CD8+ T lymphocytes are detected in patients with 
primary infection. Studies showed that beside the predominant response, in uncloned 
PBMC, to the serotype of DENV that the donors were exposed to, there was also 
presence of serotype cross-reactive responses detected (Dharakul et al. 1994; Gagnon 
et al. 1999). This is probably due to the high homology between the four serotypes of 
DENV. The kinetics of the T cell response in a secondary infection caused by dengue 
infection is also different from a primary infection. The dengue-specific memory T 
cells respond more rapidly during a secondary infection compared to naïve T cells, 
resulting in faster proliferation of dengue-specific T cells. This is also believed to be 
the same for DENV serotype cross-reactive memory T cells during secondary 
exposure to the virus (Beaumier et al. 2008; Mathew et al. 1998).  
These virus-specific CD4+ and CD8+ T cells lyse infected cells and produce 
cytokines such as interferon gamma (IFN ) and tumor necrosis factor alpha (TNF ). 
Several clinical studies have reported elevated levels of cytokines such as TFN , 
IFN  and IL-2 in patients with DHF compared to those having DF (Bethell et al. 
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1998; Green et al. 1999; Hober et al. 1993). The deregulation of the lymphokine 
production may further activate complement cascade and contribute to the overall 
pathogenesis, such as plasma leakage observed in DHF patients.  
1.3.3.  Antibody-dependent enhancement of dengue virus infection 
DENV is shown to replicate in macrophages in-vivo and cause enhanced 
infection known as antibody dependent enhancement (ADE) (Halstead 1982; Halstead 
and O'Rourke 1977). Recovery from first time infection with DENV normally 
provides a life-long immunity to the particular serotype of DENV. However, 
sequential infection by another serotype often leads to the development of the more 
severe form of illness, DHF or DSS (Halstead 2002). This ADE phenomenon occurs 
during a secondary infection when the viruses enter via non-neutralizing IgG antibody 
complexes (generated during previous infection) through idiosyncractic Fc -receptors. 
Due to the inability of the non-neutralizing antibodies to activate phagocytosis, the 
virus-IgG immune complexes escape the host defense and gain a free ride into the 
host cells. Epidemiology studies reporting higher occurrence of DHF/DSS in patients 
who have previous infection with the virus validated this hypothesis (Halstead et al. 
1970; Sangkawibha et al. 1984; Thein et al. 1997). This is further strengthened by the 
findings of increased risk of DHF experienced by infants born from dengue-immune 
mothers, probably due to the presence of pre-existing maternal dengue antibodies in 
these children (Kliks et al. 1988). However, there were also few reported cases of 
DHF/DSS patients who did not have pre-existing dengue antibodies and showed  
primary immune response, implying the possibility of other factors responsible for 




1.3.4. Genotype and viral factors involvement in pathogenesis of DHF 
All four serotypes of DENV can cause the severe form of the disease; with an 
implicated higher risk in patients infected with dengue serotype 2 virus (Burke et al. 
1988; Sangkawibha et al. 1984) or dengue serotype 3 (Messer et al. 2003) . There 
were also studies describing the existence of “virulence” and “avirulent” genotypes 
that differ in causing the severity of the disease. This was based on the observation of 
DHF/DSS epidemic appearing in the western hemisphere after the introduction of a 
southeastern Asian DENV2 genotype in 1981 (Guzman et al. 1995; Rico-Hesse et al. 
1997). Asian DENV2 genotype was also shown in in-vitro experiments to produce 
higher titers in macrophages and dendritic cells compared to the American DENV2 
genotype (Cologna and Rico-Hesse 2003; Pryor et al. 2001). As a result, it is believed 
that these Asian genotypes are more “virulent” than those native genotypes found in 
Americas and the South Pacific. 
Beside genotype difference in causing severity of the disease, the presence of 
more viruses or viral proteins in bloodstream of patient may also be responsible for 
causing DHF/DSS. Higher viremia load in patients‟ blood was found to correlate with 
the severity outcome of the disease (Endy et al. 2004; Libraty et al. 2002). Circulating 
viral protein in the bloodstream, sNS1, was also frequently found in elevated levels in 
patients with DHF (Alcon et al. 2002; Libraty et al. 2002; Young et al. 2000). NS1 is 
strongly immunogenic and there were studies done showing protection achieved 
against the disease by using anti-NS1 antibodies (Falgout et al. 1990; Henchal et al. 
1988; Schlesinger et al. 1987). Other viral protein, NS2A, NS4A and NS4B are also 
implicated to play a role in causing the severity of the disease, possibly via 
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interference in the signaling of interferon during immune responses (Jones et al. 2005; 
Munoz-Jordan et al. 2005; Munoz-Jordan et al. 2003) 
1.4. DRUG DISCOVERY OF DENGUE VIRUS 
1.4.1. Vector control 
 With no cure for dengue fever, vector control is used as an emergency 
measure throughout many countries where outbreaks are reported. Chemical 
intervention, such as space spraying, is commonly used but it is not considered viable 
either as a long-term or effective strategy. This is probably due to its perceived 
negative impact on human health and environment (Curtis and Lines 2000). 
Furthermore, once spraying activity stops, the mosquito population returns. Success 
has been reported in cases where huge amounts of resources were expended, in terms 
of both labor and costs. These included the implementation of a vigilant surveillance 
system and the strict observance of vector control programs (Erlanger et al. 2008).  
 Biological intervention is another area of research aimed at controlling the 
transmission of dengue. Mosquitoes are genetically modified (GM) to carry 
destructive genetic traits to the mosquitoes and are subsequently released to mate with 
the wild mosquitoes. One key component to the success of this strategy is the ability 
of these GM mosquitoes to survive, mate and pass on the destructive genetic traits 
(Scott et al. 2002). 
 One such biological strategy is the use of the sterile insect technique (SIT) on 
mosquitoes. It was first used in the early 1950s on the New World screwworm 
Cochliomyia hominivorax, and since its success, scientists have attempted similar 
approaches to control other disease-carrying vectors (Benedict and Robinson 2003). 
Laboratory-grown mosquitoes are sterilized by either ionizing radiation (IR) or 
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chemo-sterilization, with the first sterile mosquitoes by IR released into the wild in 
1959 by the United States Department of Agriculture in South Florida (Weidhaas et 
al. 1962). 
 Other biological interventions include genetically modifying the genome of 
these disease-carrying mosquitoes, using transposable elements or bacterial symbionts 
to introduce harmful genes into the mosquito population (Beerntsen et al. 2000; 
Ribeiro and Kidwell 1994). Another interesting approach is the shortening of the life 
span of mosquitoes by introducing life-shortening strains of the obligate intracellular 
bacterium Wolbachia pipientis into laboratory mosquitoes. These mosquitoes are then 
released to mate with the wild pool (Cook and McGraw 2010; McMeniman and 
O'Neill 2010). Results from all these studies conclude that seasonal patterns of the 
targeted species distribution and competiveness of the wild type mosquitoes versus 
the released sterile populations (Helinski and Knols 2008) are crucial determinants in 
the successful outcome of this strategy. Realizing these factors, scientists are currently 
placing more effort on their mosquito population dynamics surveillance studies and 
on the comprehension of the ecology and biology of these arthropods. 
1.4.2. Vaccine development 
 To understand the daunting task faced in developing a vaccine for dengue 
fever, we need to understand that this disease can be caused by any of the four 
serotypes of the virus. Gaining immunity against one serotype does not confer 
immunity to the other three. Another factor to consider is the antibody-dependent 
enhancement mechanism implicated with this disease when administering a 
monovalent vaccine to a patient who has previous infection with a different DENV 
serotype. Hence, the logical strategy adopted by many is to develop a tetravalent 
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vaccine that protects against all four serotypes (Halstead 1988). Furthermore, there is 
no available animal model to date that can mimic the same pathological scenarios in 
the DHF/DSS in human infection. Thus, this makes the research on the pathogenesis 
of this disease challenging. 
 To achieve global vaccination against dengue fever has been a priority of the 
WHO (Brandt 1990). Two pharmaceutical companies, Sanofi Pasteur and 
GlaxoSmithKline (GSK), are currently leading the field of dengue vaccine 
development to come up with the first live attenuated tetravalent vaccine. The Sanofi 
Pasteur vaccine candidate, ChimeriVax, is composed of recombinant live attenuated 
vaccines of all four serotype envelope genes based on a yellow fever vaccine 17D 
vector backbone (Deauvieau et al. 2007; Lang 2009). GSK, in collaboration with 
Walter Reed Army Institute of Research, developed a dengue vaccine based on a 
different strategy: their vaccine candidate is a cocktail of individual monovalent 
vaccine against each of the four serotypes of dengue virus (Edelman et al. 2003; Innis 
and Eckels 2003; Sun et al. 2003). Other approaches include the usage of reverse 
genetic techniques to introduce attenuating deletion mutations into the 3‟-untranslated 
region (UTR) of cDNA clones of DENV (Men et al. 1996; Whitehead et al. 2003), 
thereby developing recombinant sub-unit vaccines, based on the viral E proteins as 
antigens (Guzman et al. 2003; Robert Putnak et al. 2005). DNA vaccine, which 
expresses viral structural proteins to elicit immune responses that produce neutralizing 
antibodies against DENV, has also been attempted (Blair et al. 2006; De Paula et al. 




1.4.3. Targeting the E protein to inhibit viral fusion 
DENV is known to enter host cells via clathrin-mediated endocytosis (Acosta 
et al. 2009; Gollins and Porterfield 1985; Krishnan et al. 2007; Mosso et al. 2008; 
Schaar et al. 2008). The virus requires an acidic pH environment in the late maturing 
endosomes (Schaar et al. 2008; Zaitseva et al. 2010) for viral fusion with host 
membrane, in order to release its genetic material for successful establishment in the 
host. The glycoprotein envelope (E) protein mediates this viral fusion. The viral 
fusion protein of the E protein is maintained initially in the virion in a metastable 
state. This fusion protein contains a conserved, mostly hydrophobic and glycine-rich 
segment, known as the fusion peptide (FP), which is inserted into the target 
membrane during the fusion event. The energy released from the maneuvering of the 
E protein to its most stable form drives the merging of the viral membrane with the 
host membrane (Weissenhorn et al. 1999). Viral fusion proteins are classified into two 
classes: class I and class II, defined by their structural properties (Kielian and Rey 
2006; Lescar et al. 2001).  
Class I fusion protein 
The class I fusion proteins exhibit structural analogies to the cellular SNARE 
fusion proteins (Skehel and Wiley 1998; Söllner 2004). They are found in a diverse 
family of viruses such as retroviruses, coronaviruses, paramyxoviruses, and 
filoviruses. Class I fusion protein is composed of mostly alpha-helical structures and 
is characterized by having the fusion peptide, in the precursor form, at the C-terminal 
to the cleavage point. The fusion protein is then brought closer to the N terminus upon 
maturation. For example, influenza virus hemagglutinin fusion protein, at neutral pH, 
is presented in the virion as fusion incompetent precursors (HA0). Upon protein 
cleavage, this generates two subunits, HA1 and HA2, with HA1 mediating the 
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receptor attachment and the other subunit HA2 mediating the fusion event (Skehel 
and Wiley 2000). Protein cleavage also primes the fusion protein into a metastable 
fusogenic state, exposing the fusion peptide (FP) on the N terminus of the protein 
subunit HA2. Within the acidic environment of the endosomal compartment, the HA2 
undergoes radical conformation change (Huang et al. 1981), resulting in the 
dissociation of HA1 and refolding of the HA2 protein (Godley et al. 1992). The free 
energy released by this refolding and rearrangement of the HA structure at low pH is 
believed to drive the final lipid bilayer fusion between the virus membrane and the 
host membrane. 
Class II fusion protein 
Class II fusion protein is different from class I fusion protein. It is composed 
of mainly beta sheets and has an internal fusion peptide rather than N-proximal 
peptide which does not require cleavage for maturation. Class II fusion proteins 
include those found in alphaviruses and flaviviruses whose structural similarities are 
shown in figure 1-4. The E protein of DENV exists in dimeric structure at neutral pH 
with the highly conserved fusion peptide buried in a hydrophobic pocket at the tip of 
DII between DI and DIII, shielded from interaction with cellular membranes (Rey et 
al. 1995; Zhang et al. 2004). Upon encountering a drop in pH within the acidic 
compartment, selectively, highly conserved histidine residues in the E protein are 
protonated. This event triggers major rearrangement of this protein, with the 
homodimers dissociating to form intermediate monomers (Fritz et al. 2008; 
Kampmann et al. 2006; Stiasny et al. 2007). The resulting exposed fusion protein at 
the C-terminal of the E protein, primes it for contact with the host endosomal 
membrane. A flexible region between domain I (DI) and II (DII) of the E protein, also 




(A)       Alphavirus (SFV) 
(B)       Flavivirus (TBE) 
 Figure 1-4: Overall architecture of class II fusion protein of (A) Semliki 
forest virus (SFV) which is an alphavirus and (B) Tick-borne 
encephalitis (TBE) virus, which is a flavivirus that carries a class II 
fusion protein which is hidden within DI and DIII of the E dimer. The 
various domains of the E protein are highlighted in red (DI), purple 
(DII), yellow (DIII) and green (fusion protein). Histidine residues 
involved in low-pH triggered conformation of E protein are also 
highlighted in the pre-fusion structures.  
Reprinted from Trends Microbiology, 17(11), Sanchez-San Martin C, 
Liu CY, and Kielian M., Dealing with low pH: entry and exit of 
alphaviruses and flaviviruses., pg 514-521., Copyright (2009), with 




(insertion) with the host membrane during viral fusion (Modis et al. 2004; Zhang et al. 
2004). There are four loosely packed DI-DII interface peptides, H1-H4, that 
contribute to the overall flexibility within this region during the low pH catalyzed 
conformations in the E protein (Hurrelbrink and McMinn 2001). The fusion ends with 
the transformation of the E monomers into homotrimers, which then pull back the 
anchor of the E protein with the fusion peptide-inserted endosome membrane to 
complete the fusion (Allison et al. 1995; Stiasny et al. 2004). 
Small molecule fusion inhibitors 
 Cryo EM fitting of mature and immature DENV virions into their respective 
density revealed that the domains of E protein undergo major re-organization during 
the maturation event (Zhang et al. 2003). Crystallography of the trimeric post-fusion 
soluble ectodomain of E protein (sE) also showed large-scale orientation of the three 
E domains relative to each other; such as the overall differences of 35
0 
in the angular 
orientation between domain I and II 
 
in the postfusion structure (Harrison et al. 2004). 
A serendipitous discovery of a hydrophobic pocket near the hinge region of E protein 
occupied by a small detergent molecule led to an interest for designing fusion 
inhibitors targeting this pocket of E protein (Figure 1-5; Modis et al. 2003). This 
pocket is proposed to be “fit-induced” as other structures of E proteins from DENV 
and TBE do not show the existence of such a pocket; suggesting molecule that binds 
to the pocket will result in the steric hindrance to the hinge movement, hence 
hampering fusion in the process. There were several studies reported that aimed to 
identify fusion inhibitor of DENV by using in-silico screening of small molecules 
predicted to bind to OG pocket, and these resulted in the identification of several 


















Figure 1-5: A pictorial representation of the DENV envelope monomer highlighting 
the BOG site. The enlarged viewed of the groove region with solvent-accessible 
surface with 1.4 Å radius solvent probe (red) and buried surface (green for 
hydrophobic, blue for hydrophilic).  
Reprinted with permission from  Zhou Z, Khaliq M, Suk JE, Patkar C, Li L, Kuhn RJ, 
and Post CB. 2008. Antiviral compounds discovered by virtual screening of small-
molecule libraries against dengue virus E protein. ACS Chem Biol 3(12):765-775, 
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Table 1-1: Summary of small molecule fusion inhibitors of DENV 
CLogP= 3.578 
MW = 402.69 
CLogP= 6.367 
MW = 469.40 
CLogP= 6.638 




MW = 659.49 
CLogP= 0.008 
MW = 408.47 
23 
 
Peptide fusion inhibitors 
Apart from small molecule inhibitors, peptide inhibitors are also investigated 
for their ability to inhibit viral fusion. Results from these investigations led to the 
conclusion: a ligand that can bind to the intermediate conformations of the fusion E 
protein (prior to the fusion of lipid bilayer with the host membrane) can retard or 
block the fusion event (Harrison 2008). Hence, synthetic peptides, reflecting the 
various regions of the DENV E proteins, were made to test for fusion inhibition. 
These peptides are usually first screened for their affinity to the E protein. Strong 
binders are subsequently tested for their ability to block fusion and viral infection. 
Several reports have shown peptides targeting domain III and the membrane-proximal 
regions inhibit dengue fusion and result in anti-viral activity (Hrobowski et al. 2005; 
Liao and Kielian 2005; Schmidt et al. 2010). Other regions of the E protein were also 
shown to be targetable by peptide inhibitors targeting the hinge region and the inter-
domain region between domain I and II of E protein (Costin et al. 2010). 
Antibodies that block fusion 
The dengue E protein is involved in various stages of the viral infection such 
as receptor attachment, entry and membrane fusion and thus, this protein undergoes 
dynamic re-arrangements to form distinct functional conformations. The central 
domain (DI) of E protein is connected to DIII and DII by flexible linkers that allow 
the E protein to form such distinct conformations required during the various stages of 
viral infection. Antibodies that target the fusion loop of DENV E protein have been 
identified but they exhibit modest efficacy both in-vitro and in-vivo (Crill and Chang, 
2004; Gocalvez et al. 2004; Nelson et al. 2008; Throsby et al. 2006). It was puzzling 
to scientists how this fusion-loop antibodies are able to recognize the mature form of 
the virus as DENV is known to have the fusion loop buried within the DI/DIII 
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interface of the antiparallel dimer (Kuhn et al. 2002; Nelson et al. 2008; Stiasny et al. 
2006). This question is subsequently answered with the observation reported by Lok 
and colleagues whom showed that temperature can affect the affinity of a fusion-loop 
antibody (1A1D-2 Fab) to the virion, with enhanced affinity at 37 
0
C compared to 4 
0
C (Lok et al. 2008). They demonstrated that the conformation adopted by DENV E 
protein at 4 
0
C has limited access for the Fab to bind compared to the conformation 
adopted at physiological temperature. The immunoglobulin-like DIII undergoes 
significant displacement during the fusion transition. It has been demonstrated that 
both viral fusion and infection are inhibited by exogenous DIII fragments that bound 
to fusion intermediate following E trimerization (Chin et al. 2007; Chu et al. 2005; 
Liao and Kielian 2005).  Hence antibodies that bind to DIII could potentially trap 
fusion intermediates preceding viral fusion, making them promising anti-dengue tool.  
1.4.4. Targeting viral enzymes involved in viral replication 
1.4.4.1. NS2B-NS3 protease 
 NS2B-NS3 protease (NS2B-NS3pro) is an attractive target as it is a crucial 
enzyme required to cleave viral precursor polyprotein during the initial establishment 
of viral genome replication in host cell. The viral protease is a trypsin-like serine 
protease possessing a catalytic triad (His51, Asp75 & Ser135) (Bazan and Fletterick 
1989; Gorbalenya et al. 1989). The dengue protease requires the ~40 residues 
hydrophilic domain from NS2B to cleaves the newly translated polyprotein at the 
junctions NS2A-NS2B, NS2B-NS3, NS3-NS4A, NS4B-NS5 and also internal sites 
within C, NS2A, NS3 and NS4A  (Falgout et al. 1991; Lobigs 1993; Nestorowicz et 




 Structural-based studies have greatly aid in the development of inhibitors for 
dengue proteases. Brinkworth and colleagues did some pioneering work on 
deciphering the structural properties of dengue protease using sequence homology 
modeling between the DENV NS3 with HCV NS3 protease as comparison model. 
The X-ray crystal structure of NS3 protease in complex with the mung-bean 
Bowman-Birk inhibitor, although not a representative of the active form of the 
enzyme, provided the initial structural basis for studying enzyme-inhibitor interaction 
(Krishna Murthy et al. 1999). Recent development in X-ray crystallography with the 
active form of NS3 with its co-factor NS2B showed large differences in the substrate 
binding region between the NS3 structure and NS3-NS2B structure. This further 
highlights the importance of role of NS2B in the viral protease activity (D'Arcy et al. 
2006; Erbel et al. 2006). One major challenge is to find suitable inhibitors that can 
bind with high affinity to the active site of protease, given that the active site is flat 
(Erbel et al. 2006) and negatively charged (Noble et al. 2010).   
The substrate specificity of the viral protease is also investigated.  It was found that 
NS3 protease has specific binding sites for amino acid chains of the substrate(s) and 
the S1-S4 region of the substrate pocket is highly conserved across the four serotypes, 
implying the possibility of developing a pan-dengue protease inhibitor (Li et al. 2005) 
There were several studies done on peptidic inhibitors that disrupt the viral protease 
activity (Chanprapaph et al. 2005; Ekonomiuk et al. 2009; Ganesh et al. 2005; Yin et 
al. 2006). This approach is based on using peptidomimetics similar to the viral 
protease catalytic substrate. One such substrate reported was the tetrapetide benzoyl-
norleucine (P4)-lysine (P3)-arginine (P2)-arginine (P1)-ACMC (Bz-Nle-Lys-Arg-
Arg-ACMC) ( Li et al. 2005) which forms the basis for subsequent studies involving 
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HTS and SAR-based screening for more potent peptide inhibitors (Niyomrattanakit et 
al. 2006; Yin et al. 2006). 
Beside compounds that target the viral protease activity, compounds that 
disrupt the interaction of NS3 with the NS2B co-factor could be of interest in anti-
dengue drug design. There are two proposed sites (“site 1” and “site 2”) for NS2B 
binding sites, making them possible targets for allosteric inhibition (Chappell et al. 
2008). Two teams have reported their HTS screening of small molecules protease 
inhibitors that led to the identification of such non-competitive compounds (Johnston 
et al. 2007; Yang et al. 2010).  
1.4.4.2. NS3 helicase   
 The NS3 NTPase/helicase domain is responsible for the initiation of viral 
RNA synthesis by driving the energy required for this event and unwinding the 
secondary structure of the 3‟-UTR region (Takegami et al. 1995). It has a DExH-
subfamily helicase; helicases within this family have the primary sequence of a 
conserved motif called motif 2 or Walker B (Walker et al. 1982). Compared to the 
well studied HCV NS3 helicase, DENV NS3 helicase unwinding mechanism is still 
not well characterized such as the polarity of unwinding, loading strand requirements 
and specificity for duplex substrate (Eoff and Raney 2005; Lindqvist et al. 2008). 
Crystallization of NS3 helicase (Xu et al. 2006) has provided initial information about 
this enzyme and this led to the development of helicase inhibitors for DENV 
(Sampath et al. 2006). The high-degree of similarity observed among the catalytic 
regions in various flaviviral helicases also indicates the possibility of developing a 
broad spectrum anti-viral effective against all flaviviruses (Bollati et al. 2009). Since 
NS3 helicases interact with both nucleotide and nucleic acids, targeting these two 
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interactions could lead to inhibition of this viral enzyme. As reviewed by Sampath 
and colleagues, there are three strategies to design an inhibitor for helicase: (1) 
inhibition of the nucleotide binding or ATPase activity of NS3hel, (2) blocking RNA 
substrate binding or processing and (3) blocking the translocation of NS3hel 
(Sampath and Padmanabhan 2009). These inhibitors could either be competitive by 
direct competing with the substrates for binding to NS3, or bind to other sites of the 
protein to cause an allosteric effect on the enzyme. The task of finding a potent 
inhibitor against dengue NS3 NTPase/helicase is faced with difficulties such as 
toxicity of ATPase inhibitors towards the host and the lack of good physiologically 
relevant in-vitro assays that are suitable for high throughput screening (Lescar et al. 
2008).  
X-ray crystallography studies done on NS3hel bound with nucleotide revealed 
several structural features that were overall not appealing for designing nucleotide 
competitive inhibitors for NS3hel (Davis and Teague 1999; Luo et al. 2008; Wu et al. 
2005). Several studies also concluded that inhibition of the ATPase activity of NS3hel 
was not sufficient to inhibit its helicase activity.  Borowski and colleagues found that 
a broad range of structurally unrelated compounds were able to inhibit/enhance the 
ATPase activity of WNV NTPase/helicase without affecting the helicase activity and 
conversely, other compounds that stimulated the helicase activity without affecting 
the ATPase activity (Borowski et al. 2001). Two mutational studies investigated on 
dengue helicase also showed the existence of strong residual helicase activities that 
were ATPase independent (Sampath et al. 2006; Xu et al. 2005). This led to the 
debate as to whether the screening of inhibitors based on helicase assay is a wiser 
choice over NTPase assay or RNA binding assay. Co-crystal structures of NS4hel 
with RNA substrate reveal that the size of its nucleic acid substrate binding site is big 
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enough to accommodate small molecule inhibitors (Luo et al. 2008). Although it was 
demonstrated in HCV helicase with the identification of a small molecule helicase 
inhibitor QU663, the substrate binding site shows low druggability because of the few 
hydrophobic residues present in this region for compound binding (Maga et al. 2005) 
Disrupting the conformational changes of NS3hel required for its function can 
provide an alternative strategy to targeting substrate binding sites. Luo and colleagues 
recently reported the functional requirement of the inter-domain flexibility between 





) that is required for both the enzymatic 
activity and RNA replication. Hence, it may be feasible to design inhibitors that bind 
to the region of NS3 which would prevent the subsequent conformational changes 
required for the enzyme active form.  
1.4.4.3. NS5 methyltransferase  
 The capping of viral RNA, in which a guanosine monophosphate (GMP) 
moiety is covalently attached to the 5‟ end of the RNA transcript, stabilizes the 
mRNA and regulates its translation initiation (Furuichi and Shatkin 2000). This 
capping process is done by four enzymatic reactions (see figure 1-6). The dengue NS5 
methyltransferase is involved in the last two modifications: the N-7 methylation of the 
cap (guanine) by a guanine-N7-methyltransferase (N7 Mtase) and the 2‟-OH 
methylation of the first transcribed nucleotide by nucleoside-2‟-O-methyltransferase 
(2‟-O-MTase). This RNA capping process is important for mRNA stability, protein 
synthesis and also virus replication, making NS5 methyltransferase attractive target 
for anti-dengue drug design.  
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The understanding of how NS5 MTase recognizes and binds RNA capped 
structures required for viral replication is useful when designing MTase inhibitors. 
Crystal structures of dengue MTase domain in complex with its co-substrate, S-
adenosyl-L-methionine
 
(AdoMet), or its capped substrate analogues and also the 
product of the reaction, S-adenosyl-L-hohomcysteine (AdoHcy), are useful data for 
designing inhibitors against MTase (Benarroch et al. 2004; Egloff et al. 2002; Egloff 
et al. 2007; Geiss et al. 2009). Structural studies reveal both high affinity binding site 
(HBS) and secondary putative low affinity binding site (LBS) located close to the 
AdoMet binding site for the capped RNA (Dong et al. 2008; Mastrangelo et al. 2007); 
making theses sites potential drug targets. Targeting MTase has been shown to be 
successful in other viral systems, using GTP analogues and AdoMet/AdoHcy 
analogues (Li et al. 2007; Pugh et al. 1978; Woyciniuk et al. 1995). Sinefungin, a 
well-known anti-fungal AdoMet analogue, was shown to inhibit methylation and viral 
replication in another flavivirus, West Nile virus (Dong et al. 2008), making MTase a 
valid target for anti-dengue drug discovery. 










Figure 1-6: Dengue RNA 5′ cap formation. Four enzymatic modifications are 
required for cap formation that are carried out by NS3, a yet unidentified enzyme, and 
NS5 methytransferase as depicted in the diagram.  
Reprinted from Antivral Research, 80(1), Dong H, Zhang B, and Shi PY, 
Flavivirus methyltransferase: a novel antiviral target, pg 1-10, Copyright 




The knowledge of DENV RNA cap methylation is mostly derived from WNV 
MTases that exhibits a sequential event with the N-7 methylation event preceding the 
2‟O-methylation (Zhou et al. 2007). However, with the recent finding suggesting that 
DENV N-7 methylation, rather than 2‟-O methylation, is essential for DENV 
replication, inhibitors that target N-7 methlyation may be a better choice for DENV 
drug discovery (Dong et al. 2010)   
1.4.4.4. NS5 polymerase  
 The NS5 RNA-dependent RNA polymerase (RdRp) is a vital enzyme during 
viral replication as it is the core machinery for making new strands of viral RNA. This 
important function makes RdRp a target of particular interest in anti-viral drug design.  
Inhibitors that are currently developed for the polymerase are either nucleoside 
inhibitors or non-nucleoside inhibitors. High throughput screening of NS5 RdRp 
inhibitors has been greatly aided by the availability of cell-based sub-genomic RNA 
replicons containing only the non-structural proteins involved in the viral replication 
(Ng et al. 2007). Such tool not only allows the monitoring of viral replication in-vivo 
but also addresses other questions not possible in in-vitro polymerase assay, such as 
cell permeability and host toxicity. 
In flavivirus drug research, many of the nucleoside inhibitors are presented as 
pro-drugs, requiring host kinases to phosphorylate and modify the compounds into 
active forms for inhibition of the viral enzyme (Carroll and Olsen 2006; De Clercq 
and Neyts 2009). These nucleoside inhibitors target the active site of the viral 
polymerase, functioning as competitors with natural NTP substrates or/and as „chain 
terminators‟ (De Francesco and Carfi 2007). Many of the nucleoside inhibitors are 
discovered through the rational search of substrate analogues. An adenosine analogue 
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(7-deaza-2‟C-acetylene-adenosine) is one such nucleoside reported to inhibit dengue 
NS5 polymerase through termination of the viral RNA synthesis. The compound 
exhibits potency in both cell lines and animal models (Yin et al. 2009). Non-
nucleoside inhibitors are compounds that are bound to allosteric sites of the 
polymerase, affecting the conformational changes of the dynamic enzyme during 
replication, rendering the enzyme inactive. There are two potential allosteric sites 
proposed for dengue polymerase (Malet et al. 2008) that are targeted for the design of 
small molecule inhibitors. A non-nucleoside inhibitor for DENV polymerase 
(NITD002), reported by Niyomrattanakit and colleagues, was suggested to affect the 
polymerase activity by blocking the RNA template entry (Niyomrattanakit et al. 
2010). However, like the fate of many non-nucleoside inhibitors, NITD002 failed to 
exhibit anti-viral activity in cell-based assay, possibly due to cell permeability issue. 
Studies done on DENV RdRp found that the de-novo RNA synthesis of the negative 
strand is enhanced by a large stem-loop structure (SLA) located near the promoter 
region (Filomatori et al. 2006that binds and interferes with the interaction of this SLA 
region with the RdRp domains may possibly block the conformation of active viral 
polymerase, thus making this region a potential drug target.  
In summary, a structure activity relationship (SAR)-based approach is widely 
employed when looking for inhibitors of these various dengue viral enzymes. Despite 
having the knowledge of the crystal structures of these NS proteins, we have yet to 
find a potent anti-viral compound. This is often due to the challenges faced, such as 
the lack of relevant functional assays and the enigmatic complexity of dynamic 
conformational changes of these viral enzymes. 
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1.4.5. Host lipids as targets for anti-viral compounds 
 The revelation that many cellular host factors are important for replication 
fitness of the virus leads to the possibility of targeting host factors for anti-viral 
activity (Krishnan et al. 2008; Sessions et al. 2009; Tai et al. 2009). Targeting host 
factors is appealing as it removes the selective pressure of resistant mutations on the 
virus, which arise from drugs targeting viral proteins. Examples of host targets are 
host glucosidases that are involved in folding and glycosylation of viral proteins (Wu 
et al. 2002) and C-type lectin domain family 5, member A (CLEC5A), a lectin 
receptor, which is shown to involve in DHF/DSS pathogenesis (Chen et al. 2008) and 
host lipid metabolism. In the context of the work done in this thesis, I will focus on 
how host cell lipids contribute to viral infection and targeting them for anti-viral 
therapy.  
1.4.5.1. Host cholesterol metabolism 
 Lipids have been shown to be important for many viruses and are required in 
various stages of the viral life cycle. Many plus-strand RNA viruses have been shown 
to induce membranous structures in host cells, which are believed to be sites of the 
viral replication machinery (Knoops et al. 2008; Ng and Hong 1989; Schaff et al. 
1992; Welsch et al. 2009). There are implications of viral regulation on the host 
cholesterol homeostasis in order to supply lipids for the formation of these 
membranous structures (Deng et al. 2010). Cholesterol metabolism has been shown to 
be altered by many viruses, including WNV (Mackenzie et al. 2007), HCV (Fujino et 
al. 2010) and DENV (Rothwell et al. 2009). Robinzon and colleagues reported in their 
study of measles virus that genes in host cholesterol biosynthesis were up-regulated 
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during acute infection of neuronal cell lines (Robinzon et al. 2009). This led to the 
speculation that the measles virus regulates the host cholesterol synthesis to establish 
persistent infection in the host.  
 A popular class of cholesterol-lowering drugs, statins, has been shown to 
exhibit anti-viral activity against several viruses such as HIV (Amet et al. 2008), 
Poliovirus (Liu et al. 2006) and cytomegalovirus (Potena et al. 2004). For flaviviruses, 
statins were also shown to affect DENV (Rothwell et al. 2009) and WNV (Mackenzie 
et al. 2007). Statins, initially developed for treating atherosclerosis, act on inhibiting 
an important cholesterol synthesis enzyme, 3-hydroxy-3-methyl-glutaryl-CoA 
reductase (HMG-CoA reductase). There is a recent interest in using statins for HCV 
and HIV treatment, due to the frequent observations of lipid abnormalities associated 
with chronically infected patients suffering from these diseases. In one study, it was 
found that statins when used in combination with current HCV drugs resulted in a 
delay in resistance against these viral-targeted drugs (Delang et al. 2009).  
 However, there are controversial results arising from clinical studies with the 
use of statins: in one study, statin was found to improve the efficacy of HCV drug 
(Milazzo et al. 2010; Sezaki et al. 2009), whereas in another study, there was a 
noticeable increase in viral loads in patients treated with flustatin (Milazzo et al. 
2009).  These conflicting results could be due to the pleiotropic actions of statins in 
HCV infection (Lonardo et al. 2007; Milazzo et al. 2009). This discrepancy in the 
effect of statins in patients highlights a need for further clinical studies, in order to get 
a clearer understanding of the mode of mechanism of statins in fighting viral 
infections. This would help to address the validity of host cholesterol metabolism as 





1.4.5.2.  Host fatty acids metabolism 
 Fatty acids play an important role in dengue replication (Heaton et al. 2010). 
One study demonstrated that DENV NS3 protein was involved in the distribution of 
fatty acid synthase (a key enzyme in the synthesis of fatty acid) to the site of viral 
replication. In-vitro experiment showed that NS3 increases fatty acid synthesis. The 
favouring towards fatty acid synthesis in viral infection is also observed in HCV (Su 
et al. 2002; Yang et al. 2008) and HIV (Rasheed et al. 2008), hinting the possible 
regulation of fatty acids metabolism by these viruses to establish themselves in host 
cells.  
 Fatty acids, like cholesterol, have been suggested to be involved in 
maintaining structure and fluidity of the membranes associated with the viral 
replication machinery. It has been shown that saturated fatty acids, which enhance 
membrane fluidity, stimulate HCV replication, whereas the unsaturated form, for 
example, polyunsaturated fatty acid (PUFA), which decreases fluidity, inhibits HCV 
replication (Kapadia and Chisari 2005).  
 Fatty acids are also important for the post-translational modification of 
proteins. These fatty-acylated proteins are synthesized by acyltransferases that utilize 
fatty acid–CoA substrates to yield N-myristoylated proteins (Farazi et al. 2001) or S-
palmitoylated proteins (Linder and Deschenes 2007). Myristoylation of structural 
proteins of viruses is required for targeting these modified viral proteins to 
membranes that are important for processes such as cell entry and viral assembly and 
budding (Ansardi et al. 1992; Hearps and Jans 2007; Perez et al. 2004). 
Palmitoylation of viral proteins is equally important during viral infection. It has been 
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shown to be important for protein-protein interaction in HCV replication machinery 
(Yu et al. 2006) and also for coronavirus entry and assembly (Boscarino et al. 2008; 
Shulla and Gallagher 2009).  
 In summary, host fatty acid metabolism is regulated by viruses during primary 
infection, and this could facilitate the formation of specialised membranes required 
for the replication machinery. It is also required for targeting viral proteins to 
designated sites of the host cells for viral infection. Hence, suppressing fatty acid 
synthesis to suppress viral infection could be an avenue for anti-viral strategy. 
Targeting fatty acid synthase has been shown to reduce viral infection in-vitro, so 
perhaps an approach of designing novel FASN-targeted small molecule inhibitors 




1.4.5.3. Host ceramides 
 Ceramide, a molecule composed of a sphingosine and a fatty acid, is produced 
by hydrolysis of sphingomyelin by sphingomyelinases, or via de-novo synthesis 
catalysed by serine-palmitoyl-CoA transferase and ceramide synthase (Marchesini 
and Hannun 2004). Cellular ceramide levels were found to be elevated within twenty-
four hours of infection with human cytomegalovirus (HCMV), concurrent with the 
stimulation of de-novo sphingolipid metabolism (Machesky et al. 2008). Sindbis 
virus, rhinovirus and adenovirus were also found to induce host ceramide synthesis, 
and were affected when ceramide production was inhibited (Grassme et al. 2005; 
Kanj et al. 2006; Ng and Griffin 2006). Gassert and colleagues showed that measles 
virus counteracts host immune response by activating host sphingomyelinases and 
ceramide accumulation in T cell membranes (Gassert et al. 2009). This resulted in an 
aberration in the overall actin cytoskeleton remodelling in T-cells, which was required 
for functional activation of host immune responses against the invading pathogens. 
 Another similar mechanism is observed in the impairment of host‟s innate 
response by lymphocytic choriomengitis virus (LCMV) via manipulation of host 
ceramide levels. This was observed in mouse model having acid sphingomelinase 
(ASMase) deficiency. The suppressed cytotoxic activity of cytotoxic T lymphocytes 
(CTL) was reported in these ASMase-/-mice and resulted in a delayed clearance of 
LCM viruses from the organs of these mice (Herz et al. 2009). Results showed that 
ASMase was required for efficient fusion of the host secretory lysosomes with the 
plasma membrane of CTL, required for virus clearance. It was therefore proposed that 
LCM virus impaired the fusiogenic of these two by disrupting ceramide levels in the 
membrane via ASMase suppression (see figure 1-7). 
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 In HIV infection, ceramide plays a role in the entry step of infection. 
Galatosylceramide (GalCer) was discovered to act as a co-factor in HIV envelope 
binding to CD4 cells (Hammache et al. 1998). Studies showed that stimulating 
ceramide accumulation in host membranes resulted in inhibition of HIV, underlying 
the importance of ceramide levels in host cell membranes. This was consequently 
looked into as a possible target for HIV drugs (Nguyen and Taub 2004). Several 
analogs of GalCer were shown to inhibit HIV infection (Mahfoud et al. 2002; Villard 
et al. 2002). For HCV, ceramide accumulation at the plasma membrane by SMase 
treatment triggers the internalization of CD81, a major receptor of HCV, resulting in 
viral inhibition (Voisset et al. 2008). In one study, the use of ceramide analogue, N-
(3-Hydroxy-1-hydroxymethyl-3-phenylpropyl) dodecanamide (HPA-12), which 
inhibits ceramide trafficking from the endoplasmic reticulum to the Golgi apparatus, 
caused a suppression in HCV production (Aizaki et al. 2008). A separate study from 
the isolation of a secondary fungal metabolite led to identification of a novel HCV 
inhibitor, NA255. The mechanism of action of NA255 was elucidated to be targeting 
the de-novo synthesis of sphingolipids (Sakamoto et al. 2005). This compound was 
also found to inhibit the association of HCV non-structural proteins with lipid rafts.  
 The role of ceramides in flaviviruses is still underexplored. Recently, JEV 
production was shown to be enhanced with SMase treatment
 
of cells, and that 
regulation of host ceramide level is important for JEV viral entry and egress (Tani et 
al. 2010). As reviewed by Han and Jiang, perhaps with the recent advancement in 
mass spectrometry, extensive sphingolipids profiling (known as sphingolipidomics) 
could allow us to gain more insights into the relationship between host sphingolipid 






















Figure 1-7: A cartoon depicting the mechanistic effects of ceramides in mediating 
cell bending and fusion. (A) Induction of ceramides via hydrolysis of sphingomyelin 
by acid sphingomyelinase (ASMase). (B) In biomembranes, lipids are 
asymmetrically distributed with sphingomyelin largely confined to the luminal and 
extracellular leaflets. Generation of cone-shaped ceramide within the luminal leaflet 
of vesicular membranes results in regions of bending thereby promoting full fusion 
of, e.g., lysosomes with CTL.  
Reprinted from Immunobiology, 213(3-4), Utermohlen O, Herz J, Schramm M, and 
Kronke M., Fusogenicity of membranes: the impact of acid sphingomyelinase on 









1.5. SCOPE AND OUTLINE OF THIS THESIS 
 The main objective of this thesis is to find novel compounds that inhibit 
dengue infection. The possibility of targeting a viral factor (viral fusion) or host factor 
(host cholesterol metabolism) using small molecule compounds will be investigated. 
 (1) Dengue virus fusion inhibitors 
Viral fusion is a crucial event for the release of viral genomic material into host 
cytoplasm. This leads to the establishment of viral replication. The envelope (E) 
protein of dengue virus mediates the fusion event with host membrane. In Chapter 3, a 
rational approach is used to identify small molecules that can inhibit viral fusion. 
First, a cell-cell fusion assay will be developed to enable the screening of compounds 
in a 96-well plate format. Compounds identified from the cell-cell fusion assay will be 
validated and characterized for their anti-viral activity. 
 (2) A study of mechanism of action of NITD770, a compound discovered 
to inhibit host cholesterol biosynthesis 
Work done in Chapter 4 is an extension of a study previously reported by Rothwell 
and colleagues (2009). They found that modulation of host cholesterol metabolism 
can influence dengue infection and that targeting the host mevalonate pyrophosphate 
decarboxylase (MVD) resulted in the suppression of viral replication. NITD770, a 
small molecule inhibitor of MVD, was found to inhibit dengue infection. Its mode of 
action and anti-viral activity will be validated in this study. 
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 (3) U18666A, a cholesterol transport inhibitor: The identification and 
mechanism of action study of a new type of anti-dengue compound 
In Chapter 5, the anti-viral effect of U18666A will be investigated. It is an amphiphile 
known to arrest cholesterol transport and inhibit cholesterol biosynthesis in cells. This 
study will investigate how the compound affects viral entry and viral replication, 





2. METHODS AND MATERIALS 
2.1. CELL-BASED VIRAL FUSION ASSAY 
 The primary assay was adapted from a method previously described by 
Randolph and Stollar (1990). Mosquito cell line, C6/36, of a cell density of 1.5 x 10
5 
cells per well were seeded together with dengue virus strain TSV01 DENV at a 
multiplicity of infection (MOI) of 0.1 in 96-well plates (Nunc, Denmark). Three days 
post-infection, each compound was added to the infected cells and incubated for one 
hour at 28°C. The medium was acidified to induce fusion by adding 5 L of 0.5 M 2-
(N-morpholino) ethanesulfonic acid (MES) (pH 5.0), and incubated for 1 hour at 
37°C. The fused cells were then stained with propidium iodide (0.025 mg/mL) for 30 
min at 28°C before proceeding to fluorescence reading with a Tecan Safire II plate 
reader using an excitation wavelength of 537 nm and an emission wavelength of 617 
nm, with a bottom fluorescence measurement, and 3 readings per well. The quality of 
the assay can be determined by the dimensionless Z‟ value based on positive and 
negative control samples. The calculation, Z‟=1-(3xSDblank+3xSDpositive)/ (|Meanblank-
Meanpositive|), takes into account the signal dynamic range and the data variation 
associated with the signal measurement (Zhang et al. 1999). Only assays with a Z‟ 
value above 0.5, indicating a good dynamic range and a low variation, were accepted. 
2.2. CELL-BASED FLAVIVIRUS IMMUNODETECTION (CFI) ASSAY 
This is an in-house based assay developed in NITD. A549 cells were seeded 
one day before with a cell density of 20,000 cells per well in a 96-well plate. The cells 
were then cultured in 2%FBS in Hams F12 with 1% Penicillin/Streptomycin. Next 
day, the cells were infected with 1.09 L (5500,000 PFU/mL stock) of NGC in the 
presence of 0.5 L compound (100X) in 48.41 L cell culture medium. A set of two-
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fold serial dilutions was performed for each compound tested. After 48h incubation at 
37
0
C, viral antigen production was quantified by immuno-detecting using the anti-E 
antibody, 4G2) and secondary goat anti-mouse antibody conjugated with horse radish 
peroxidise. The dose-response curve was determined using nonlinear regression 
analysis by Prizm. 
2.3. CELL CULTURES 
 All mammalian cell lines used in this thesis were cultured at 37
0
C with 5% 
CO2 except for insect cell line, C6/36 that was cultured at 37
0
C without the 
requirement of 5% CO2. Cell culture media and antibiotics, Penicillin and 
Streptomycin used in 1:100 dilution, were purchased from Gibco, Invitrogen, U.S.A. 
Fetal bovine serum (FBS) from Hyclone, Thermo Scientific, U.S.A. was supplied as 
10% v/v during cell maintenance.  
2.4. CYTOTOXICITY DETERMINATION 
 BHK21 cells were seeded with a density of 2 x 10
4 
cells/well into a 96 well 
plate (NUNC, U.S.A) one day before treating them with increasing concentration of 
compound for 3 days. The CellTiter
®
 Glo assay kit (Promega Corporation, Madison, 
WI, USA) was then used to determine the viability of the cells by quantifying the 
cellular ATP levels via a luciferase-based reporter system. 
2.5. DRUG SYNERGY STUDY USING MACSYNERGY II 
 Drug interaction was performed on Huh7 DENV replicon cells using 
MacSynergy II platform, which look at synergy of two drugs based on the Bliss 
independence model (Prichard and Shipman 1990).  The combination matrix was set 
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up with a 6 x 6 dose matrices with 5 serially diluted concentrations (33.3 M, 11.1 
M, 3.7 M, 1.2 M and 0.4 M) of each compound. A three dimensional plot was 
done which displayed synergy as peak above the calculated additive plane and 
depression below this plane as antagonism. A series of eight replicates were 
calculated to be statistically significant at 95% confidence level. The strength of 
synergy between the two compounds were determined by looking at the volume under 
the curve whereby synergy volume of <25 M
2%
 is additive or non-synergy, 25-50 
M
2%
 is minor but significant synergy, 50-100 M
2% 
is moderate synergy and >100 
M
2% 
is strong synergy.  
2.6. EXPRESSION AND PURIFICATION OF DENV NS5 PROTEIN AND 
MUTANTS 
 Competent BL21rIL Escherichia coli (E.coli) cells were transformed with NS5 
expression vectors and grown in LB plates containing 25 g/mL of Kanamycin at 
37
o
C overnight. Next day, the colonies were scrapped and inoculated into 600mL 
fresh LB media (25 g/mL of Kanamycin) and incubated at 37
o
C with shaking (220 
rpm) until an OD595 of 0.6 to 0.8.  Induction of protein expression was done by 
addition of 0.4 mM of isopropyl-b-D-thiogalactopyranoside (IPTG) and placed in a 
pre-cooled 16
0
C incubator with shaking set at 220 rpm for overnight. Cells were then 
harvested by centrifugation at 6000 rpm for 10 minutes at 40
o
C and sonicated (34 % 
amplitude, 10 sec on, 10 sec rest, 5-7 min using Digital Sonifier
® 
homogenizer, 
Branson, USA) in NTA-A buffer (20 mM Tris, 500 mM NaCl, 2 mM Me, 5% 
Glycerol) with protease inhibitor (complete, mini, EDTA-free, Roche, U.S.A.) and 
0.01% CHAPS. Resulting cellular debris were removed by centrifugation at 20500 
rpm for 1 hr at 4
oC. Supernatant was then passed through 0.22 μm filters before 
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loading into a HisTRAP HP, 5 mL column (GE Healthcare, U.K) pre-equilibrated 
with cold NTA-A using AKTA FPLC Chromatographic System (GE Healthcare, 
U.K). The HIS-tagged NS5 protein was eluted from column using Buffer NTA-B (20 
mM Tris-HCl at pH7.4, 500 mM NaCl, 2 mM ME, 5% Glycerol and 500 mM 
imidazole). Fractions as well as peak fractions were analyzed by 10% sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel stained with 
InstantBlue (Expedeon, UK) before pooling, desalting and concentrating to a volume 
of 0.5 mL using Amicon Ultra tube (Millipore, Billerica, USA) with a molecular 
weight cut-off of 50 kDa. The protein was then further purified by gel filtration using 
Superdex 200 10/300 GL column (GE Healthcare, U.K) that was pre-equilibrated 
with 20 mM Tris, 550 mM NaCl, 2 mM Me, 5% Glycerol. Collected fractions were 
once again analyzed by SDS-PAGE and stained to identify fractions enriched with 
NS5. These enriched fractions were subsequently pooled together to be concentrated 
to approximately 8 mg/mL before snap freezing in liquid nitrogen and stored at -80
0
C. 
2.7. HPLC/APCI/MS ANALYSIS OF CHOLESTEROL AND 
ZYMOSTEROL  
 Control and treated cells were washed with PBS and harvested. Lipid was 
extracted from cells in chloroform: methanol (1:2) and the organic fraction was dried 
to lipid film. The dried lipid fraction was re-constituted in chloroform: methanol (1:1) 
for mass spectrometry analysis. Sterols were analyzed using an Agilent HPLC 1100 
system (Agilent) coupled with an Applied Biosystems 3200 QTrap mass spectrometer 
(Applied Biosystems, Foster City, CA). In brief, separation of sterols was carried out 
using an Agilent Zorbax Eclipse XDB-C18 column (i.d. 4.6 × 150 mm) (HPLC 
conditions were as follows: (1) chloroform: methanol 1:1 (v/v) as the mobile phase at 
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a flow rate of 0.5 ml/min; (2) column temperature: 30°C; (3) injection volume: 10 ml. 
The LC-MS instrument was operated in the positive atmospheric pressure chemical 
ionization (APCI) mode with a vaporizer temperature of 500ºC and corona current of 
3 µA. Multiple reaction monitoring (MRM) transitions for endogenous sterols as well 
as cholesterol-26,26,26,27,27,27-d6 (CDN Isotopes Inc., Quebec, Canada) and 
zymosterol-2,2,3,4,4-d5 (Avanti Polar Lipids, AL, USA) were used for sterol 
quantification (Huang et al. 2006). 
2.8. INDIRECT IMMUNO-FLUORESCENCE MICROSCOPY 
2.8.1. Immuno-fluorescence microscopy for DENV envelope in C6/36 cells 
 C6/36 cells were infected with viruses with a multiplicity of infection (MOI) 
of 1 for two days at 28°C. The infected cells were fixed with 2% paraformaldehyde in 
PBS for 15 min and washed with PBS. The fixed cells were then incubated with 1% 
FBS in PBS for 1 hr, and labeled with monoclonal antibody 4G2 (1:50 dilution from 
in-house antibody from hybridomas) against the E-protein overnight. This was 
followed by PBS washings before labeling with the secondary antibody, FITC-labeled 
goat anti-mouse IgG (1:1000 dilution; catalogue number #F0257 from Sigma, 
U.S.A.). The cells were counterstained with DAPI to visualize the nuclei. The labeled 
cells were observed through a laser-scanning
 








2.8.2. Immuno-fluorescence microscopy for viral trafficking and co-labeling of 
DENV envelope protein with endosomes 
 BHK21 cells were infected with dengue virus strain NGC (with a multiplicity 
of infection (MOI) of 50) for various time points at 37°C to look at the trafficking of 
viruses. The infected cells were then fixed with 4% paraformaldehyde in PBS for 20 
min, washed with PBS, permeablized with 0.05% saponin, 15 FBS, 10 mM Hepes, 10 
mM Glycine in PBS, pH 7.5 for 30 min, and labeled with monoclonal antibody 4G2 
(1:50) against the E-protein and either with anti-early endosomal antigen 1(1:50 
dilution; rabbit polyclonal; catalogue number #2411 from Cell Signaling technology 
TM
, U.S.A) or anti-Lamp1 (1:100 dilution; rabbit polyclonal; catalogue number 
#ab24170 from Abcam, U.K. U.S.A)  overnight for co-labeling. This was followed by 
PBS washings before labeling with the secondary antibody, conjugated with Alexa 
Fluor 488 and 594 dyes (1:800 dilution; Catalogue number: #A10680 & #A11012 
from Molecular probes, Invitrogen, U.S.A) . The cells were counterstained with DAPI 
to visualize the nuclei. The labeled cells were observed through a laser-scanning
 
microscope (Leica FW 4000). 
2.8.3. Cholesterol staining using FILIPIN III 
 For cholesterol staining, the cells were fixed with 4% PFA and washed several 
times with PBS before staining for 1 hour in dark with 70 g/mL Filipin III (Cayman 
chemicals, U.S.A). The labeled cells were observed through a laser-scanning
 





2.9. IN- VITRO FLUORESCENCE POLYMERASE ASSAY 
 The polymerase activity was determined using BBT-ATP (synthesized by Jena 
Bioscience GmbH, Germany), as a substrate for the polymerase reaction 
(Niyomrattanakit et al. 2011). This adenosine nucleotide was modified by attaching 
the BBT fluorophore group to the -phosphate of adenosine triphopshate. During the 
polymerization, adenosine monophosphate was incorporated into the RNA chain, and 
BBTppi was released as a by-product of the reaction. BBTppi , was then cleaved by calf 
intestinal alkaline phosphatase (CIP) to produce inorganic phosphate (Pi) and the 
alcohol, 2´-[2-benzothiazoyl]-6´-hydroxybenzothiazole (BBT), which gave 
fluorescence. The experimental procedure is described below. 
The RNA template, 3‟UTR-U30 (5‟-bio-U30-AACAGGUUCUAGAACCUGUU-3‟ 
purchased from Dharmacon, USA) was re-suspended to 200 M in a buffer consisting 
of 50 mM Tris-HCl (pH 8.0) and 150 mM NaCl in 0.1% diethyl pyrocarbonate 
(DEPC) water. The solution was then incubated at 60
0
C for 5 min and placed at room 
temperature to allow the formation of the intra-molecular hairpin.  
 To measure the polymerase activity, a master-mix of 20 nM of NS5 protein 
and  50 nM of the RNA template were added into the RdRp assay buffer (50 mM 
Tris-HCl (pH 7.0), 1 mM MnCl2 and 0.01% Triton) and left at room temperature for 
30 min of incubation. Aliquots of 10 L of the master-mix were transferred into wells 
of a 96 well assay plate (black plates from Corning Costar, USA). This was followed 
by 10 L of 2 M BBT-ATP in the same RdRp assay buffer. We then did a time-
course study of 120 min. At every 10 min interval, a volume of 20 L of stop buffer 
(200 mM NaCl, 25 mM MgCl2, 1.5 M DEA) containing 25 nM calf intestinal alkaline 
(CIP), was added to terminate the reaction. The released BBT was monitored (after 1 
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hour incubation at room temperature) at ex/em 422/566 nm using Tecan SaffireII 
(Tecan, USA).  
2.10. ISOLATION OF LIPID RAFTS 
 This protocol was modified from a published protocol (Lee et al, 2008). 
BHK21 cells were washed two times with ice cold PBS and scraped into falcon tubes. 
The pelleted cells were homogenized in low salt buffer (LSB) containing 10 mM Tris-
HCL, pH 7.5, 25 mM KCl and 5 mM MgCl2 with 1% triton on ice. Nuclei and 
unbroken cells were removed by centrifugation at 1000 g for 8 min. The post nuclei 
supernatant was then overlaid on a sucrose gradient composed of 10%-55%-75% and 
subjected to 16h centrifugation at 38000 rpm using a SW41 rotor (BECKMAN, 
U.S.A.) at 4
0
C. The fractions were isolated in 1mL aliquots and cleaned up using a 10 
kDa filter (Millipore, U.S.A.). The cleaned fractions were then loaded to a SDS-
PAGE and viral proteins, NS3 and NS4B (GeneTex, Inc. #GTX103349), were 
immuno-blotted for lipid raft associations. 
2.11. LIPID EXTRACTION 
 Cells or other types of samples were re-suspended in 100 L of buffer (PBS, 
or other buffer depending on application). A volume of 0.6 mL of chloroform: 
methanol (1:2) was added and mixed by vortexing thoroughly for one minute. This 
suspension was then incubated on ice and subjected to vortexing for every 5 min of 
incubation on ice (performed twice). A further incubation period of 15 min on ice was 
done before addition of 300 L of chloroform and 200 L of water and mixed by 
vortex. The samples were centrifuged at ~8000 g force for 2 min at 4
0
C. The organic 
phase (bottom layer) was collected and dried and stored at -80
0
C.  When setting up 
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the lipids for analysis, lipid pellet was re-dissolved in 100 L of chloroform: 
methanol (1:1). 
2.12. LIPOSOME-BASED VIRAL FUSION ASSAY 
 The assay was modified from a previously described experiment (White and 
Helenius 1980).  Liposomes were prepared from a phospholipid (Avanti Polar Lipids, 
Alabaster, Ala.) mixture with a 1:1:1:1.5 molar ratio of phosphatidylcholine (PC; 
from egg yolk, Avanti), phosphatidylethanolamine (PE; prepared by 
transphosphatidylation from egg PC, Avanti), sphingomyelin (Sph; from bovine 
brain) and cholesterol. The amount of lipids used was 1 µmol PC, 1 µmol PE, 1 µmol 
Sph, 1.5 µmol Chol. The lipid mixture was then dried under a stream of nitrogen gas 
and reconstituted in HNE buffer (5 mM HEPES, 150
 
 mM NaCl, 0.1 mM EDTA, pH 
7.4) containing 10 mg/mL of trypsin (from bovine pancreas, Sigma, U.S.A). The lipid 
mixture was extruded through two pieces of polycarbonate membrane (0.2 µm hole 
size, Whatman, Clifton, NJ, USA) with a Mini-Extruder (Avanti, Polar Lipids, Inc., 
Alabaster, AL). Liposomes were stored at 4°C and used within one week. Fusion 
reactions were performed in 0.1 mL final volume containing 100,000 particles of 
purified viruses and 1 mM of trypsin-containing liposome. The samples were adjusted 
to the indicated pH values by adding a small pre-titrated volume of 0.1 M MES and 
0.2 M acetic acid, and incubated for 2 min at 37°C for fusion to occur. The reaction 
was then neutralized to pH 8.0 using a pre-titrated volume of 0.1 M NaOH, and 
incubated at 37°C for an hour to allow trypsin digestion. The integrity of viral capsid 
was determined by SDS-PAGE of the reaction mixture followed by immuno-blotting 




2.13. PLAQUE ASSAY FOR VIRAL TITER DETERMINATION 
 BHK21 cells (ATCC, U.S.A.) were seeded with a cell density of  2x10
5
 per 
well in a 24 wells plate (Nunc, Denmark) one day prior to infection. Undiluted and 
10-fold dilutions of viral supernatant were prepared in RPMI-1640 medium 
containing 2% FBS and antibiotics (Pen Strep), and were loaded (0.2 mL) onto each 
well of BHK21 cells. After incubating the cells for 1 hour  at 37°C (with 5% CO2),  
the virus inoculums were replaced with 0.5 mL of 0.8% methylcellulose Aquacide 
(Calbiochem, USA) containing 2% FBS in RPMI-1640. After 4 days of incubation at 
37°C with 5% CO2, the overlay medium were fixed with 3.7% formalin in a formalin 
tank for 30 minutes, washed with tap water, and stained with 1% of crystal violet (200 
L). The plates were then dried in 50
0
C oven and the plaques were visually counted . 
2.14. PURIFICATION OF DENGUE VIRUS 
  The experimental procedures were performed as previously described (Kuhn 
et al. 2002). Briefly, the virus was centrifuged overnight (15 h) using a Beckman type 
19 rotor at 30,000 x g.
 
The virus pellets were then allowed to soak in HNE buffer (5 
mM HEPES, 150
 
mM NaCl, 0.1 mM EDTA, pH 7.4) for 4 h on ice before thorough 
re-suspension by pipetting. Two different types of medium were used to set the 
discontinuous gradients in this thesis that are described below. 
2.14.1. Dengue virus purification using potassium tartrate. 
 Overlay the re-suspended viral harvest to a SW41 tartrate gradient of 1.5 mL 
35% (w/v) potassium tartrate in HNE-buffer, followed by 1.5 mL fractions of 30%, 
25%, 20%, 15% and 1 mL fraction of 10% potassium tartrate in HNE (Fig.2A). 
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Subject the gradient to centrifugation for 2 hours at 4
0
C  in a Beckman SW41 rotor at 
a setting of 125,000 x g. The fractions were harvested in 1 mL aliquots. 
2.14.2. Dengue virus purification using Optiprep. 
 The re-suspended viruses were overlaid to a SW41 Optiprep gradient of 1.5 
mL 55% (w/v) Optiprep in HNE-buffer, followed by 1 mL fractions of 45%, 40%, 
35%, 30%, 25%, 20% and 15% Optiprep in HNE (Fig. 2-1). Subsequently, the 
gradient was subjected to centrifugation for 2 hours at 4
0
C  in Beckman SW41 rotor at 












A                                                                 B                      
Figure 2-1: A cartoon representation of the gradient set up for (A) 
Potassium-tartrate medium and (B) Optiprep medium. 
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2.15. QUANTITATIVE REAL-TIME RT-PCR 
 Total RNA was extracted from viral supernatant using the RNeasy kit from 
Qiagen (USA). Reverse transcription was performed using the SuperScript™ III 
Reverse Transcriptase kit (Invitrogen, USA) with random hexamer primers (1.5 g) 
(Roche, Switzerland). The reaction was carried out at 25°C for 10 min, 50°C for 60 
min and 75°C for 15 min. For real-time PCR, a 20 μL reaction mix was set up using 4 
μL of cDNA, 10 L of  iQTM SYBR®Green Supermix (BioRad, USA) and 10 nM of  
primers. The sequences of the primers used were: Forward 5′-ACA AGT CGA ACA 
ACC TGG TCC AT-3′  and Reverse 5′-GCC GCA CCA TTG GTC TTC TC-3′ (Laue 
et al. 1999). PCR reactions were then cycled at 95°C for 3 min, followed by 40 cycles 
of 95°C for 10 sec, 60°C for 30 sec and 72°C for 30 sec in the iCycler Thermal Cycler 
from the iQ5 Real-Time PCR Detection System (BioRad). A standard curve was 
established using a dilution series of NGC viral RNA extracted from a known titer as 
determined by plaque assay. 
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2.16. RAISING AND SEQUENCING RESISTANT VIRUSES 
 NITD770-resistant DENV-2 was generated by passaging the DENV-2 on
 
A549 cells in the presence of NITD770. For each round of passaging,
 
cells (2 x 10
5
 
per well) in 24-well plates were infected
 
with 100 µL of DENV-2 with an MOI of 0.1 
in the presence
 
of 10 M  or 20 M of NITD770. Passage 1 (P1) to passage 10 were 
performed.
 
For each passage, viral supernatants were harvested at 48 hours
 
post 
infection, viral titers were then quantified by plaque assays. The resistant pool in P10 
was further passaged for three passages (P13) in 10 M NITD770 before using it to 
check the establishment of resistance to the compound. Viral RNAs from passage 13 
were extracted
 
from the culture supernatant using a QiAamp viral RNA minikit
 
(Qiagen, Valencia, CA). The RNAs were subjected to amplification
 
using SuperScript 
III one-step RT-PCR kits (Invitrogen). The
 
PCR products were gel purified and 
sequenced using the Sanger
 
method provided by commercial company. 
Fragment 
Primer 
I.D Primers Sequence 
Nucleotide 
position 
1 d2s23 5‟- AGTWGTTAGTCTACGTGGAC 1 -20     
 
d2a18 5'- CCACTGCCACATTTCAGTTC 2455-2474 
    
2 d2s5 5'- GGTGACACAGCCTGGGATTT 2182-2201 
 
d3a14 5'- ACTGTGATCATTAARTTGTGGGA 4334-4356 
    
3 d2s9 5'- GCATTTTRGCCAGTTCTCTCCTA 4175-4197 
 
d2a10 5'- TACGCCCTTCCRCCTGCTTCA 6477-6497 
    
4 d2s13 5'- GCAGACAGAAGGTGGTGTTTT 6193-6213 
 
d2a6 5'- CATGGTAWGCCCAYGTTTTGT 8468-8488 
    
5 d2s16 5'- CAGGAAGTGGATAGAACCTTAGCA 7669-7692 
 
d2a23 5‟- AGAACCTGTTGATTCAACAG 10704-10723 
 
Table 2-1: Primers used for amplification of dengue viral genome. 
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 Total RNA was extracted from viral supernatant using the RNeasy kit from 
Qiagen (USA). A combined one-step reverse transcription and PCR amplification was 
performed using the SuperScript™ III Reverse Transcriptase/ Platinum ® Taq Mix kit 
(Invitrogen, USA) with random hexamer primers (1.5 g) (Roche, Switzerland). The 
cDNA reaction was carried out at 55°C for 30 min, 94°C for 2 min followed by PCR 
amplification at 40 cycles of 94
0
C for 15 sec, 55
0





C for 2:30 min with a final extension cycle of 68
0
C for 5 min using 1 g of 




2.17. REPLICON ASSAY FOR VIRAL REPLICATION STUDY 
 In-house stably transfected dengue replicons (Ng et al. 2007) were used in this 
thesis. Subgenomic genotype 1b HCV replicon cell line used was from Ralf 
Bartenschlager/ReBLikon GmbH.  Non-cytopathic Venezuelan equine encephalitis 
virus (VEEV) replicon was a kind gift from Nancy L. Davis, University of North 
Carolina. . Please see table 2-2 below for information on the cell seeding density and 
culturing medium used for the respective replicon. 
Cell Line Cell seeding density Cell culture medium 
Dengue replicon in Huh7 20,000 2% FBS, DMEM 
Dengue replicon in A549 10,000 10% FBS, Hams‟ F12 
Dengue replicon in BHK21 10,000 2% FBS, RPMI 
HCV replicon in Huh7 10,000 10% FBS, DMEM 
VEEV replicon in BHK21 10,000 5% FBS, DMEM, High glucose 
Table 2-2: Seeding density and cell culture conditions for replicon cell lines 
 The next day, the seeded cells were placed in fresh medium containing  2% 
FBS (instead of 10% FBS) and no selection compounds (e.g. puromycin, G418.) The 
compounds to be tested were then added in 2-fold serial dilution in the range of 0.195-
100uM. The cells were incubated with the compounds for 48 hours before detection 
using EnduRen™ (Promega) added at 1:1000 dilution and incubated for 1hour before 
the luminescence was read. Using Prism v.4 (Graphpad software, San Diego, CA) 
software, the relative fluorescent unit (RFU) or luminescence reading was plotted 
against the log transformation of the concentration of the compound and a sigmoidal 




2.18. TRANSMISSION ELECTRON MICROSCOPY 
 The cell culture medium was removed from the cells and rinsed once with 
lukewarm PBS gently and quickly before fixation in 2.5% glutaraldehdye for an hour 
at room temperature. This was followed by three times PBS wash and treatment with 
1% osmium tetroxide for another hour at room temperature in the fume cabinet. The 
fixed cells were then washed three times in PBS for 5-10 min in each wash. The cells 
were finally scraped into eppendorf tubes and centrifuged at low speed to create a cell 
pellet for gelatin packing (6-10%) at 4
0
C for 45 min to solidify. The gelatin-embedded 
cell pellet was then soaked in 2.5% glutraldehyde for overnight at 4
0
C. Next day, the 
gelatin-embedded cell pellet were cut into 1-2 mm cubes and dehydrated successively 
in ethanol (25% to 50% to 75% to 95% to absolute ethanol) and followed by absolute 
acetone. After dehydration, the cubes were infiltrated with resin, Epon-Resin (Pelco, 
Clovis, CA, USA) and left in 60
0
C oven for 24 hours to polymerize the resin. The 
resin-embedded cubes were then cut to obtain ultrathin (70-90 nm) sections. The 
ultrathin sections were then stained with 3% uranyl acetate for 10 min, rinsed with 
water and then stained with lead citrate for 10 min, followed by rinsing with water. 
The processed sections were viewed using a transmission electron microscope (model 
1010, Jeol Ltd., Akishima, Japan).  
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3. DISCOVERY OF SMALL MOLECULE FUSION INHIBITOR OF 
DENGUE VIRUS 
3.1. INTRODUCTION 
 Dengue virus (DENV) is an enveloped virus belonging to the Flaviviridae 
family that includes other significant disease-causing members such as yellow fever 
virus (YFV), West Nile virus (WNV), and tick-borne encephalitis virus (TBE) 
(Chambers and Monath 2003). DENV is transmitted to humans via the bite of an 
infected mosquito (Vasilakis and Weaver 2008; Wang et al. 2000). Reported dengue 
cases are on the increase, with an emerging trend of dengue fever affecting both the 
affluent segment of society and the poor in tropical countries (Mathers et al. 2007; 
Normile 2007). The four serotypes of DENV (serotype 1-4) can cause a range of 
symptoms, from a mild fever to severe hemorrhagic manifestations (Chambers and 
Monath 2003; Kuno 1995). There has been an on-going effort to develop a vaccine 
for dengue fever since the 1940s (Batson et al. 2003; Mahoney et al. 2011). Vaccine 
development for DENV is challenging due to the antibody-dependent enhancement 
concern (Halstead et al. 1970) and the need to create a tetra-valent vaccine for 
protection against the four serotypes (Halstead 1988; Whitehead et al. 2007). An 
alternative approach to vaccine development is to develop anti-viral compounds to 
treat dengue infection. The multiple steps in DENV infection cycle such as viral 
entry, viral membrane fusion, replication, virus particle assembly and maturation are 
all potential anti-viral targets. 
 DENV enters the cell mainly by receptor-mediated endocytosis (Acosta et al. 
2008; Suksanpaisan et al. 2009; van der Schaar et al. 2007) followed by viral 
envelope (E) protein mediated membrane fusion. The low pH-dependent fusion event 
between the viral membrane and the host endosome membrane releases the viral 
genetic material into the cytoplasm (Mukhopadhyay et al. 2005). The DENV E-
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protein is composed of  three main domains, with the central domain (Domain I) 
flanked by the immunoglobulin-like C-terminal domain (Domain III) and the 
dimerization N-terminal domain (Domain II), that carries the fusion peptide (Modis et 
al. 2004). The DENV E-protein belongs to the class II category of viral fusion 
proteins, which consist mainly of beta-sheets, compared to class I fusion proteins, 
which contain a more alpha-helical content (Kielian 2006). Other distinct 
characteristics of class II fusion proteins are the possession of an internal fusion 
peptide and the requirement for low pH initiation of viral fusion (Kielian and Rey 
2006).  
 Upon lowering of the pH, the E-protein undergoes major conformational 
changes, with the particular region between Domain II and Domain I, known as the 
“hinge” springing upwards to bring the fusion peptide closer to the host membrane for 
fusion to occur (Modis et al. 2003). This hinge region is believed to be important 
during the early event of fusion. In the crystallization study reported by Modis and 
colleagues, a small detergent molecule, n-octyl- -D-glucoside ( OG), was found to 
occupy a hydrophobic pocket near the hinge region; mutations within this binding 
pocket resulted in alteration of pH threshold for fusion. This has been interpreted as 
an avenue to look for occupants in this potentially druggable pocket in order to inhibit 
dengue viral fusion.  
 In this chapter, a screening program (Fig.3-1) that aims at finding small 
molecules that can inhibit DENV E-protein mediated membrane fusion is reported. 
By combining in-silico virtual screening with a 96-well based functional assay, and a 
low throughput secondary fusion assay, a novel compound, NITD448, was identified 
to inhibit DENV membrane fusion and viral production. 
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In-silico search for small molecules 
that fit the hydrophobic pocket of 
envelope protein of dengue virus.
Primary screening







Figure 3-1: A diagram depicting the outline of the screening program to look for small 






3.2.1. In-silico virtual screening to build a focused library of dengue envelope 
protein binding compounds 
Structure used as a target for in-silico docking of molecules onto the hydrophobic 
pocket of E protein 
This study (done my Dr Ida Ma and Dr John Priestle from Novartis) used 
similar in-silico approach as reported previously by my colleagues in NITD (Wang et 
al. 2009) to define the βOG ligand (reported by Modis et al., 2003) as the ligand-
binding site with potential interaction grids around this ligand generated. Each E-
protein monomer forms its own βOG -binding pocket without direct contribution from 
the neighboring molecule. Although both chains were fully defined, the B chain was 
selected for the docking model as it possessed overall lower temperature factors, 
implying that its coordinates were more accurately determined. All solvent molecules 
were removed. There were three glycosylation sites on each chain. Since the 
glycosylation sites were far away (>25A) from the βOG binding site, they were also 
removed during virtual screening. The Protein Preparation module of Maestro 
(Schrödinger LLC, Portland, OR, USA) was used to prepare the protein for docking. 
The protein structure was also energy-minimized, with hydrogen atoms added, and 
their positions determined to maximize internal hydrogen bond formation. 
Selection criteria for molecules predicted to bind to the hydrophobic ligand of E 
protein 
From over 1 million compounds of the Novartis in house compound archive, 
85,000 were removed as structural duplicates, possessing molecular weight >660, >2 
undefined chiral centers or >12 freely rotatable bonds. The remaining compounds 
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were expanded for unknown chirality and alternative charge states using Pipeline 
Pilot (Accelrys Software Inc., San Diego, CA), generating 2.4 million structures to 
dock. These were docked using Glide SP (standard precision, Schrödinger LLC) on a 
Linux cluster. No constraints, e.g. a compulsory specific hydrogen-bond formation, 
were applied. Pipeline Pilot was used to sort the compounds by Glide_gscore and the 
top 3000 scoring compounds were kept. These were re-scored using consensus 
scoring (CScore) as implemented in Sybyl (Tripos, Inc., St. Louis, MI). The scoring 
results were normalized and combined. Low-scoring isomers (e.g. same molecules, 
different charge state) were removed and the remainder clustered with Pipeline Pilot 
using Functional Class FingerPrint, 6-bond radius fingerprints and a similarity 
distance threshold of 0.4 to remove some of the very similar compounds. The 
remaining 1367 top-scoring unique poses were then visually inspected until 
acceptable compounds were selected. The same procedure was carried out for docking 
the Novartis in-house natural product collection except that the chemical property 
limits for acceptable compounds was relaxed considerably, e.g. up to 15 rotatable 
bonds were accepted. In total, a library of 365 high-scoring, chemically reasonable 










Figure 3-2: A schematic representation of the virtual screening process used to 
assemble a focused library of small molecules for the primary fusion assay.  The OG 
ligand, located in the region of DENV envelope protein important for fusion, was 
used to define the ligand-binding site. 
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3.2.2. Development of a medium throughput cell-based fusion assay to screen a 
focused compound library 
 Randolph and Stollar reported dengue infected C6/36 cells undergo cell-cell 
fusion (also known as syncytium) upon low-pH exposure (Randolph and Stollar 
1990). This cell-cell fusion phenomenon is believed to be mediated by the viral E 
protein expressed on the infected cell surface. Immuno-fluorescence labeling of non-
permeabilized dengue infected cells allows visualization of E-protein on the cell 
surface without labeling of E-protein present in the cell interior. As shown in figure 3-
3A, E-protein is expressed on the cell surface of infected cells, including the interface 
between adjacent cellular membranes. Incubating at low pH of infected cells resulted 
in widespread cell-to-cell fusion (Fig. 3-3D).  A cell-based fusion assay based on this 
cell-cell fusion property of the infected mosquito cells was developed to facilitate 
screening of Novartis compounds for fusion inhibition in a 96-well plate format 
Propidium iodide (PI) staining was used to quantify the formation of cell-cell 
fusion. This method is based on the observations that viral protein-induced membrane 
fusion can damage membrane integrity (Bonnafous and Stegmann 2000; Frolov et al. 
2003). PI dye cannot penetrate intact cellular membranes, resulting in very little 
staining of uninfected cells (Fig. 3-3B) or in infected cells maintaining a neutral pH 
(Fig. 3-2C). However, infected cells exposed to low pH showed bright PI labeling 
(Fig. 3-3D), allowing a fluorescent readout of cell-cell fusion. As a control, treatment 
with 4G2, a monoclonal antibody known to bind to the fusion loop of the E-protein 
(Crill and Chang 2004; Henchal et al. 1988) before exposure to low pH, inhibited cell 
fusion and PI staining (fig. 3-3E). In contrast, treatment of the infected cells with 
9F12, a monoclonal antibody against Domain III of the E-protein, which is distal from 
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Figure 3-3: Low pH induced fusion of dengue infected C6/36 cells mediated by 
viral E-protein on the cell surface. (A) Cells infected with dengue virus display 
viral E-protein (green) on the cell surface shown by immunofluorescent labeling of 
fixed non-permeabilized cells. Nuclei were counterstained with DAPI (blue). (B) 
Uninfected cells did not fuse under acidic conditions, as shown in phase contrast 
(left panels), and did not exhibit appreciable propidium iodide (PI) staining (right 
panels). (C) Infected cells three days post-infection maintained at neutral pH also 
did not fuse and did not show PI staining. (D) Infected cells showed widespread 
fusion under acidic conditions resulting in PI staining of the syncytiated cell mass. 
(E) Infected cells three days post-infection that were pre-incubated for one hour 
with antibody 4G2 against the fusion loop of the E-protein, did not fuse and did not 









 Optimization experiments were performed (together with Mr Andy Yip from 
Novartis) to develop this cell-based fusion assay into a robust 96-well format. Cell 
seeding density was found to be an important factor in obtaining a reliable cell fusion 




 cells per well (Fig. 3-4A). The assay 
signal was relatively insensitive to the Multiplicity of Infection (MOI) from 0.01 to 
0.3, whereas a higher MOI of 0.5 reduced the assay signal (Fig. 3-4B). As expected, 
cell fusion was found to be pH-dependent, starting at an acidic pH value lower than 
6.6 (Fig. 3-4C).  
 Using the above cell-based fusion assay, 365 small molecules identified from 
the in-silico docking were tested in triplicate at 25 M. The assay had an a good Z‟ 
factor of 0.7. It was found that compound NITD448 (Fig. 3-5A) reproducibly 
inhibited the PI-mediated fluorescent staining in a dose-responsive manner, with a 
50% inhibitory effect (IC50) of 6.8 M (Fig. 3-5B). These results suggest that 











































































































































Figure 3-4:  Characterization and optimization of the primary cell-cell fusion assay. 
(A) The wells of a 96-well plate were seeded with different cell densities and 
subsequently infected with dengue virus using an MOI of 0.1, followed by the 
acidification, staining and fluorescent readout on day 3 post-infection. Results 
shown are from four independent experiments, using two batches of cell stocks (P10 
and P17). (B) Wells were seeded with a density of 1.5 x 10
5
 cells per well and 
subsequently infected with different MOI, followed by the acidification, staining and 
readout on day 3 post-infection. Results are from two independent experiments. (C) 
Wells were seeded with a density of 1.5 x 10
5
 cells per well and infected with 
dengue virus with an MOI of 0.1. On day 3, post-infection cells were exposed to 
media of different pH before staining and readout. Results are from two independent 
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Figure 3-5: Compound structure and inhibition of fusion in primary assay. 
(A) The molecular structure of fusion inhibitor NITD448. (B) Compound 
NITD448 inhibited fusion in the cell-cell fusion assay with an IC50 of 6.8 
M. Error bars represent standard deviations from two replicates. 
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3.2.3. Compound NITD448 inhibits E protein-mediated membrane fusion in 
liposome-based fusion assay 
 Based on liposome fusion assays using isotope-labeled virus (White and 
Helenius 1980), a non-radioactive content-mixing fusion assay using immuno-
detection of nucleocapsid protein was developed. Purified dengue virus mixed with 
liposomes containing the protease trypsin. Membrane fusion between these two 
particles allowed the trypsin to access the interior of the virions, resulting in digestion 
of the capsid (C) protein (Fig. 3-6).  
 Firstly, two different purification protocols were tested to find out which 
protocol would result in higher yield of viral particles for subsequent use in the 
liposome based fusion assay. It was noted that there were different viral banding 
profile obtained for the two protocols: the tartrate protocol resulted in a single visible 
viral band at 20% of tartrate, whereas three bands (20%, 25% & 30% optiprep) were 
visible for the optiprep protocol (Fig.3-7A). Further quantification of the viral titers of 
each of the gradient fractions resulted in the observation that the optiprep protocol had 
a higher recovery of infectious viruses compared to tartrate protocol (Fig.3-7B). SDS-
PAGE analysis was performed to examine the purity of the viruses isolated from the 
fractions of optiprep gradient, as shown in figure 3-8, the envelope protein and 
possibly capsid protein were the main components in the purified fractions from the 
gradient. From this finding, optiprep protocol was used for purification of viruses 


































Figure 3-7: Purification of DENV using two different mediums for density 
gradient. (A) Photographs taken after high-speed centrifugation resulting in 
concentration of viral bands around 20% for tartrate gradient and 20%, 25% and 
30% for optiprep gradient. (B)Viral titer quantification using plaque assay to 
determine fractions of the gradient containing the most infectious viral viruses. 
Tartrate Optiprep 
 pfu/mL  % recovery  pfu/mL  % recovery 
Input 1.8 x 107  Input 5.9 x 107  
10% 2.0 x104  0.11 15% 7.0 x105  1.19 
15% 1.5 x105  0.83 20% 1.0 x106  1.69 
20% 7.0 x105 3.89 25% 1.3 x107 22.03 
25% 8.0 x105  4.44 30% 1.3 x107  22.03 
30% 1.5 x105 0.83 35% 8.0 x105 1.36 
32% 1.0 x105  0.56 45% 7.0 x105  1.19 
35% 2.5 x104  0.14 50% 4.5 x104  0.08 
   55% 3.5 x103  0.01 




















Figure 3-8: SDS-PAGE analysis to check for the purity of the purified viruses. Two 
resolution SDS-PAGE gels of 12% and 15% Bis-acrylamide were run. The viral 





















 Western blot analysis showed intact C-protein when the mixture of virus and 
liposomes was kept at neutral pH. In contrast to mixture that was exposed to low pH, 
degradation of C-protein was observed, but only if trypsin was present in the 
liposomes (Fig. 3-9A). Addition of the 4G2 antibody against the E-protein was able to 
prevent degradation of C-protein in a dose-dependent way. The results indicate that 
the assay reliably monitors the pH-dependent E-protein membrane fusion. 
Compound NITD448 was tested in this liposome based virus fusion assay and showed 
a clear and robust dose-dependent inhibition of membrane fusion (Fig. 3-9B). Taken 
together, the results clearly indicate that compound NITD448 can inhibit E-protein 
mediated membrane fusion.  
 
Figure 3-9: Inhibition of fusion in secondary assay. Mixtures of purified dengue virus 
and liposomes were exposed to various conditions and analyzed for the presence of 
intact viral capsid protein. (A) Capsid protein was not degraded if liposomes did not 
contain trypsin regardless of pH (lanes 1,3, 5), but if liposomes contained trypsin the 
viral capsid protein was degraded when the mixture was exposed to low pH causing 
fusion between liposomes and dengue virions (lanes 2, 4, 6). This degradation could 
be prevented in a dose dependent manner if the mixture was pre-incubated with 
antibody 4G2 against the fusion loop of the Envelope protein (lanes 7, 8, 9).  (B) 
Similarly, compound NITD448 could inhibit fusion and trypsin degradation of capsid 
in a dose dependent manner. 
 
 Lane     1          2        3           4           5          6         7          8           9 
 Lane     1               2               3          4                5             6       
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3.2.4. Anti-viral activity of compound NITD448 
 To determine the anti-viral activity of compound NITD448, DEN2 NGC-
infected cells were treated with various concentrations of the compound for three 
days, followed by determination of viruses produced in the supernatant. NITD448 
was found to inhibit dengue infection with an EC50 value of 9.8 M (Fig.3-10A). Its 
cytotoxicity was determined at a CC50 of 49 M, resulting in a selectivity index of 5 
(Fig. 3-10B). 
 Next, time-of-addition experiments were carried out to investigate the 
mechanism of viral inhibition. NITD448 was added to cells 1 hour before, during, or 
1 hour post viral infection. As shown in figure 3-10C, the compound did not reduce 
virus production when present just before or after infection. NITD448 exhibited the 
strongest inhibition on viral production when added during the 1 h virus infection of 
the cells. The results once again indicate that the compound inhibits membrane fusion 
during viral entry into the cells. 
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Figure 3-10: Antiviral activity of compound NITD448. (A) Cells were treated with 
a concentration range of compound NITD448 during infection with dengue virus 
for three days. Supernatant was subsequently harvested and analyzed by 
quantitative RT-PCR expressed in equivalents of plaque forming units (PFU) per 
mL. The compound showed a dose dependent inhibition of viral yield with an EC50 
of 9.8 M. (B) Cells were treated with a concentration range of compound 
NITD448 during infection with dengue virus for three days. Infected cells were 
then lysed and quantified using CellTiter
®
 Glo assay kit for cell cyto-toxicity. The 
compound showed a CC50 of 48.7 M. (C) Reduction of viral yield could be 
observed when NITD448 was present only during the one hour of infection, i.e. 
when virus and cells were incubated together, but not when cells were incubated 





 In the efforts towards developing an anti-viral treatment for dengue, a 
screening program was set up in NITD, aimed at identifying dengue E-protein 
mediated membrane fusion inhibitors. Previous studies only investigated the anti-viral 
activity of molecules, with the potential to bind to the E- protein, as predicted from in-
silico docking (Wang et al. 2009; Yennamalli et al. 2009). The approach used in this 
study complements in-silico studies, with functional assays that monitor membrane 
fusion. A two-step screening approach was developed employing a 96-well primary 
cell-based fusion assay and a subsequent low-throughput secondary liposome-based 
fusion assay to validate viral fusion of primary hits. The primary assay was based on 
previously published (Randolph and Stollar 1990) cell-cell membrane fusion of 
dengue-infected cells, leading to syncytia formation, brought about by cell surface 
expressed E-protein. This study reports a convenient novel detection method for 
quantification of syncytia formation that allows monitoring of fusion activity in a 96-
well plate. 
 A secondary assay was established based on a cell-free system containing 
purified dengue virus and liposomes, allowing detection of content mixing of these 
two membrane enveloped particles as a readout of the fusion event. By using antibody 
to detect capsid protein in Western blot to simplify the assay, there was no need for 
production and purification of radioactively labeled dengue virus.  
Since the primary assay capacity did not allow high throughput screening, a 
focused library was made that was composed of compounds predicted to bind inside a 
putative binding pocket identified in the E-protein (Modis et al. 2003). Screening this 
focused library resulted in three primary hits, one of which was validated in the 
secondary assay, showing dose dependent inhibition of fusion.  
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 The confirmed fusion inhibitor NITD448 proved to have anti-viral properties 
exhibiting an EC50 of 9.8 M, comparable to the IC50 of 6.8 M found when titrated 
into the cell-based fusion assay. This anti-viral effect works only if the compound is 
present during the viral entry phase of infection, consistent with the mechanism of 
action of a fusion inhibitor. 
 NITD448 is a novel structure, different from dengue entry inhibitors published 
previously (Li et al. 2008; Wang et al. 2009; Yennamalli et al. 2009). GLIDE docking 
suggests that the carboxylate on the chromenone ring of NITD448 interacts with 
Lys128 and Gln52 of the E-protein, with the trifluoro-phenyl motif of the molecule 
well buried into the hydrophobic OG pocket (Fig. 3-11). This is similar to the 
chloro-phenyl-thiophene tail of the previously reported dengue entry inhibitors such 
as compound 6 reported by our colleague in NITD (Wang et al. 2009), an effective 
small molecule that shows good sub-micromolar EC50 in cell-based flavivirus 
inhibition assay and was shown by immuno-labeling to cause virus particles 
arrestment in the acidic endosomal compartments. Interestingly, compound 6, when 
tested in the cell-cell fusion assay and the liposome-based validation assay, failed to 
exhibit any inhibition in these assays (data not shown). This raised a question about 
the limitation of the fusion assay used in this screening program, such as the 
possibility of failing to identify a good anti-viral compound that was not showing 
activity in the cell-cell fusion assay.  
In terms of its drug-like properties, based on the criteria stated by Lipinski‟s 
rule of five, it had a calculated octanol-water partition coefficient log P value (CLogP 
= 7.95) more than 5 and a molecular weight (659.49) of more than 500 Daltons. This 
might present a problem of oral bioavailability and hence, further chemical 
modification is necessary for this small molecule.  
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Chemists in NITD had also tried to examine the molecular properties of the 
other primary hits to look for similarity between the molecular properties of the two 
hits and that of NITD448 but found none. Furthermore, a family of compounds (from 
the Novartis compound library) that was structurally similar to NITD448 was tested 
on the primary fusion assay. They all were unable to block fusion in the liposome 
based fusion assay and none showed better EC50 in cell-cell fusion assay (data not 
shown). Hence, these compounds were not considered for drug discovery. The 
original NITD448 was not available in sufficient amount in Novartis compound 
archive. It is therefore not possible to perform further in-vivo validation of this 
compound (such as pharmacokinetic studies or mice studies) to further confirm its in-
vivo efficacy. 
 Conceding the above fact that NITD448 was not selected as a candidate for 
drug discovery, it is the first reported small molecule with confirmed fusion inhibition 
activity against dengue. It may be the starting point for further development of more 
potent compounds with higher selectivity index. NITD448 can also be used as a tool 
in future screening campaigns for fusion inhibitors. In addition, it may be of value in 















Figure 3-11: Putative binding mode of NITD448. The proposed binding modes by 
GLIDE for NITD448 (ball-and-stick) in DEN2 E-protein (PDB# 1OKE): (A) side 
view (B) top view.  The protein surface is coded grey and purple for hydrophobic and 





4. A STUDY OF THE MODE OF ACTION OF NITD770, A SMALL 
MOLECULE INHIBITOR OF DENGUE VIRUS 
4.1. INTRODUCTION 
 Targeting host processes essential for viral infection is an alternative approach 
to look for anti-viral compounds. This study is a continuation of a previous effort in 
targeting host cholesterol metabolism pathway host for anti-dengue drug discovery 
(Rothwell et al. 2009). Host cholesterol pathway genes were initially examined via a 
candidate gene-by-gene approach and by using siRNA to knock down the various 
biosynthetic genes in host cholesterol pathway. Pharmacological inhibitors of the 
various enzymes in the pathway were also tested for an effect on dengue replication. 
Inhibition of mevalonate pyrophosphate decarboxylase (MVD), an intermediate 
enzyme of the sterol biosynthesis, results in suppressed dengue replication (figure 4-
1). These efforts led to the discovery of a novel host target, MVD. A small molecule 
from the Novartis archive compound library, NITD770, a mevalonate inhibitor, was 
tested in dengue replicon system and was found to exhibit anti-viral activity. 
In this study, the anti-viral profile of NITD770 was investigated and found to 
be effective at sub-micromolar concentration with a good selective index. The anti-
viral efficacy of the compound was also investigated in other flaviviruses and non-
flaviruses. Validation experiment done on NITD770 confirmed that it was not a MVD 
inhibitor. This led to a series of cross-disciplinary approaches to determine the 



























Figure 4-1: The disruption of host cholesterol biosynthesis using various inhibitors 
that target the intermediate biosynthesis enzymes resulted in dengue inhibition 
(figure modified from Rothwell and colleagues, 2009). Anti-dengue compound 
NITD770 was identified from a screen of compounds that targets the enzyme, 




4.2.1. NITD770 shows specific anti-viral activity across several flaviviruses 
NITD770 was found to inhibit dengue activity in cell-based flavivirus 
inhibition (CFI) assay, replicon assay and plaque assay (see Table 4-1). It showed a 
general half maximal effective concentration (EC50) within 0.5-1.5 M. This 
compound was also effective against other members of the flaviviridae family, having 
a EC50 of 3.5 M in HCV replicon cells and 0.6 M in yellow fever virus CFI assay 
(done by Miss Haoying Xu). When tested against non-flaviviruses, the compound lost 
its potency, as observed with alphaviruses (highlighted in blue), Venezuelan equine 
encephalitis virus (VEEV) (done by Dr Paola Florez de Sessions) and Chikungunya 
virus ( work done by Mr Liu Wei). 
Assay EC50 M CC50 M 
Dengue (NGC strain) A549 CFI 0.58 50-100 
Dengue (NGC strain) A549 Plaque  0.6 50-100 
Dengue (NGC strain) BHK21 Plaque 0.5 50-100 
Dengue (NGC strain) A549 replicon 0.6 16.6 
Dengue (NGC strain) Huh7 replicon 1.4 67 
Yellow Fever (17D vaccine strain) A549 CFI 0.6 >100 
HCV Huh7 replicon 3.5 >100 
VEEV BHK21 replicon >20 >100 
Chikungunya (Ross strain) BHK21 Plaque >10 >100 
 
Table 4-1: Anti-viral activity profile of NITD770 in several assays. The potency of 
the compound is determined by the calculation of the concentration at 50% inhibition, 
IC50 value. Yellow fever A549 CFI assay was done by Miss Haoying Xu, VEEV 
BHK21 replicon assay was done by Dr Paola Florez de Sessions and chikungunya 





4.2.2. The lack of inhibition of NITD770 in MVD enzymatic assay and host 
cholesterol biosynthesis pathway 
 NITD770 was reported to be a MVD inhibitor in the 1990s. At that time, a 
crude lysate of HepG2 cells (enriched with MVD) was used to measure the 
conversion of radioactive C14 labeled mevalonate di-phosphate to cholesterol. In order 
to validate once more the compound‟s inhibition on MVD, an affinity-purified 
recombinant MVD was used in the enzymatic assay carried out by Dr Christian Noble 
in NITD. As shown in figure 4-2, 100 M of NITD770 did not affect the MVD 
enzymatic activity.  
Further investigations were carried out to examine whether NITD770 affects 
the host cholesterol metabolism. This was done by measuring the total cholesterol 
levels and zymosterol levels in host cells. Zymosterol is an intermediate product along 
the sterol biosynthesis pathway. An increase in zymosterol levels indicates an increase 
in the host sterol biosynthesis. Cells were treated with NITD770 for 48 hours 
followed by lipid extraction using organic solvent. Next, Dr Guanghou Shui from 
LipidProfiles in NUS performed the quantification of lipids using gas-
chromatography mass spectrometry (GC-MS). As shown in figure 4-3, neither total 
cholesterol levels (p-values for BHK21=0.40 and A549=0.24) nor zymosterol levels 



















Figure 4-2: Mevalonate diphospho decarboxylase (MVD) enzymatic 
assay. This was done by measuring indirectly the hydrolysis of ATP 
by MVD. The substrate for MVD is MevPP and mimic used as a 
positive control of inhibiting the enzyme MVD. This experiment was 














































































































































































































































































Figure 4-3: Determination of total cholesterol and zymosterol level in cells 
using GC-MS. The values were normalized with total protein concentration. 
The cells used for quantification were control (CTL), treated with NITD770 
and treated with the inactive analogue, NITD419. T-test (unpaired unequal 
variance) was performed to compare the significant differences using p 
value  of <0.05). 
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4.2.3. Validating host lipids as potential host target of NITD770 
 We enlisted help from our collaborators (Novartis, NIBR) to look for likely 
host targets using HIP-HOP in yeasts. This is a genome-wide approach done in yeasts 
to look for potential drug target or mechanism of action by looking at the cellular 
response to perturbations caused by the drug of interest (Hillenmeyer et al. 2010). In 
the haploid insufficiency profiling (HIP) assay, a library of approximately 6,000 
haploid yeast mutants (each strain having one copy of the gene deleted) is assessed for 
their growth ability in a culture medium with the presence of the drug. The deletion of 
one gene copy sensitizes the yeast mutant to the drug effect and hence, mutant that 
does not grow well in the presence of the drug indicates that particular gene as a 
possible target. Each mutant has a “tag” containing hybridization signal that can be 
identified in an array-style format using high-density oligonucleotide array (Giaever 
et al. 2002). Homozygous profiling (HOP) is an alternative approach used to identify 
gene required for growth in the presence of the drug. For HOP, the library of yeast 
mutants consists of strains having both copies of a particular nonessential gene 
deleted (homozygous deletion mutants). The identification of the slow grower 
highlights the possible pathway affected by the drug of interest.  
The preliminary HOP data had a relatively clean profile, with only a few 
sensitive and significant strains (due to confidentiality issue, data is not shown here). 
These hits are similar to a few compounds previously screened in other HOP assays 
done by our collaborators (these yeast profiling experiments were not related to our 
HOP profiling), that were found to be affecting host lipid rafts. Others have 
previously reported the compounds that inhibit the same genes (co-inhibition) may 
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have similar chemical structure and mechanism of action (Giaever et al. 2004), 
suggesting that NITD770 may target the lipid raft pathway in the host. 
 The integrity of lipid rafts in NITD770-treated cells was examined to see 
whether the compound targeted lipid rafts, as suggested by the yeast HOP studies. 
Lipid rafts were isolated from detergent resistant membrane (DRM) fractions, using 
detergent extraction and sucrose gradient density centrifugation. Two lipid rafts 
markers, anti-flotilin and anti-caveolin, were used to identify the DRM. As shown in 
figure 4-4A, there was no observed effect on the lipid raft integrity (fractions 2 to 4) 
isolated from cells treated with NITD770 compared to the control untreated cells. In 
the next experiment, immuno-fluorescence microscopy, using cholera toxin sub-unit 
A to label lipid rafts, was performed to examine the lipid raft integrity. The compound 
methyl-beta-cyclo-dextrin (MBCD) was used as a positive control, which is known to 
disrupt lipid rafts by extracting cholesterol from the cell plasma membrane. As shown 
in figure 4-4B, MBCD treatment destroyed the cholera toxin staining for lipid rafts on 
the cell plasma membrane. NITD770 has no effect on the lipid raft integrity because 
the treated cell plasma membrane labeled by cholera toxin showed similar labeling 



























Figure 4-4: Looking at the integrity of lipid rafts in cells upon treatment 
with NITD770. (A) Lipid rafts were isolated using detergent (1% triton) on 
ice. Flotilin and caveolin were used as markers for fractions enriched with 
lipid rafts. (B) Lipid rafts were stained using cholera toxin sub-unit A 




4.2.4. Raising resistant mutant viruses against NITD770 
 Drug-resistant isolates are obtained by continuously passaging the viruses in 
the presence of anti-viral compound. Following several rounds of infection cycle, 
some mutant viruses may become increasingly resistant to the compound. The 
genome for these resistant viruses is then sequenced to identify mutations that may 
contribute to the resistance displayed. My colleagues, Dr Gu FENG and Mr Cedric 
NG, used this technique to find out the likely viral targets of NITD770. They started 
the experiment with two concentrations of NITD770, 10 M and 20 M, and 
harvested resistant viruses at 48 hours intervals. As shown in figure 4-5A, there was 
an increase in resistance to 10 M NITD770 in passages 8, 9 and 10. From this, they 
took passage 10 10uM resistant viruses to validate the resistance achieved in this pool 
of mutants. Data in figure 4-5B shows that mutants were resistant to both 10 M and 


















































































Figure 4-5: Raising resistant viruses against NITD770. (A) BHK21 cells were used 
to infect with dengue viruses, in presence of either 10 M or 20 M of compound. 
The newly produced viruses were harvested 48 hours post infection and used to re-
infect new uninfected BHK21 cells in succession up to ten passages. The viral titer 
of each passage was determined using plaque assay and expressed as plaques per 
mL of virus harvest (PFU/mL). (B) The resistant viruses from 10 M P10 batch 
were further passaged for three passages (P13) in 10 M NITD. P13 resistant 
viruses were used to determine the resistance against up to 20 M of NITD770 
against the wild type viruses. This set of experiments was performed once by Mr 
Cedric NG and Dr Gu Feng from NITD. 
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4.2.5. Isolation and sequencing of individual isolate of viruses resistant to 
NITD770 found conserved mutations within the NS5 polymerase, near to 
the surface of the RNA entry tunnel 
 The genomes of six isolates were sequenced and the mutations are presented 
in figure 4-6. Five mutations were found in these resistant viruses, one in NS4B and 
four located within NS5. Of these mutations, only three are conserved across all four 
serotypes of DENV and are located within the RdRp of NS5. 
Like WNV, DENV RdRp adopts a right-hand structure with three 
subdomains: fingers, palm and thumb (Malet et al. 2008; Yap et al. 2007). The three 
resistant mutations of NITD770-resistant virus are located in the palm domain of 
RdRp. The mutation at nucleotide 535A-V is located near to the helix 13, and 
mutations 607G-A and 615E-G are located within helix 16 of the palm domain. As 
seen in figure 4-7, all three mutations are clustered around the palm domain, near to 
the surface of the RNA template tunnel.  
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 NGC (NITD) wt   NGC (770-Mut)  Region  
nt position  nt seq  a.a seq  a.a position  nt seq  a.a seq   
7361 CGTGACTCAAG LCVTQVL 179in 
NS4B  
CGTGATTCAAG LCVIQVL NS4B 
(in the middle of 
transmembrane 4)  
9176 CACCGCAGGAT DDTAGWD  535 in NS5  CACCGTAGGAT DDTVGWD NS5 (RdRp) 
conserved  
9392 CCTATGGACTC GTYGLNT 607 in NS5  CCTATGCACTC GTYALNT NS5 
(RdRp) conserved  
9416 TATGGAAGCC TNMEAQL 615 in NS5  TATGGGAGCC TNMGAQL NS5 
(RdRp) conserved  
9225  AGAAATGGTA  NEEMVT  551 in NS5  AGAAAAGGTA  NEEKVT NS5 
(RdRp) not conserved  
Table 4-2: Sequencing results of the genome of the NITD770 resistant viruses. In total, six isolates from the 20 M 
resistant dosage pool were sequenced. The mutated nucleotide and amino acid residues are highlighted in both wild type 







Figure 4-6: Location of the conserved mutations in the NITD770-resistant viruses. A 
schematic representation of the structure of the DENV-2 NS5 polymerase domain 
with the three subdomains (Finger, Thumb & Palm) highlighted. The three 
conserved resistant mutations are colored in orange and the tryptophan residue near 
to these mutations is colored in pink. 






4.2.6. Studying the effect of NITD770 and its resistant mutations on the 
polymerase activity of NS5 protein 
 Observations made from the resistant mutations all point to the palm domain 
of the NS5 RdRp region that is highly conserved across many structurally known 
polymerases. Hence, it would be interesting to find out if NITD770 interferes with the 
viral polymerase function. 
 An in-vitro RdRp assay was carried out to examine the effect of the resistant 
mutations on the viral polymerase activity. This was done by introducing the resistant 
mutations into NS5 protein (single mutants, double mutants and triple mutants) and 
measuring the polymerase activity of each NS5 mutant proteins, in comparison to 
wild type NS5 protein. Only the triple mutant protein exhibited a noticeable increase 
in the polymerase activity (slope of best-fit line = 249.2) compared to wild type 
protein (slope of best-fit line = 144.1) (Figure 4-8A). 
 Next, the effect of NITD770 on the viral polymerase activity was studied to 
see if the engineered mutant NS5 can rescue the suppression of polymerase activity 
by the compound. Increasing concentration of NITD770 did not significantly inhibit 
the RdRp reaction (Figure 4-8B), having a calculated IC50 of 42 M. When the triple 
mutant protein was tested against NITD770, the mutant protein did not relieve the 
dose-response inhibitory effect of the compound on the viral polymerase activity 
(Figure 4.8B; an IC50 value of 49 M).  
Based on the data from these two studies, it was concluded that these resistant 
mutations resulted from an indirect consequence of creating a faster polymerase, in 





NS5 WT vs mutants



















NS5 WT vs mutants (NITD770)















Figure 4-7: Determination of polymerase activity of NS5 and its resistant mutants. An 
in-house in-vitro RNA-dependent RNA polymerase (RdRp) assay was set up to 
measure polymerase activity, by measuring the amount of fluorescent-RNA substrate 
incorporated into the polymerase. (A) A profile of the polymerase activity of the 
various resistant NS5 proteins in the absence of inhibitor. (B) NITD770 was added in 
an increasing concentration to wild type (WT), double mutant (A535V+G607A) and 









 NITD770‟s anti-dengue mechanism of action was investigated in this study. 
Even though it was reported as an MVD inhibitor in the archive compound library, 
during the validation experiment, NITD770 was confirmed to be not an inhibitor of 
MVD. Discrepancies between the results from the initial cell-free MVD assay and the 
validation experiment could be due to the presence of unknown factors in the crude 
cell lysate used in the initial MVD enzymatic experiment, compared to the purified 
recombinant MVD used in this study. Although MVD was not a target of NITD770, 
given the acceptable anti-viral profile and potency of this compound, it was kept in 
the drug discovery program.  
 From anti-viral profiling experiments, NITD770 exhibited a good anti-viral 
activity with an EC50 value of low micro molar range and a wide selective index 
(CC50/EC50) of more than 100. It was also shown to be specific to viruses of 
flaviviridae family compared to alphaviruses.  
 As the mechanism of action of NITD770 was unknown, a chemo-genetic 
profiling of this compound was done in yeast to determine other host targets. HIP-
HOP data showed an effect of NITD770 on the yeast lipid raft pathway, implying host 
lipid raft to be a likely target. However, based on data obtained from the lipid-raft 
detergent extraction experiment and the immuno-staining of lipid-rafts by cholera-
toxin, it was concluded that lipid rafts in host cells were unaffected by NITD770. The 
inconclusive outcome from the HIP-HOP experiment could be due to the limitations 
of this assay such as the target of NITD770 is not being represented in the yeast 
mutant pool used. It is an important issue to consider when using this approach, as 
some human genes are not represented in the yeast genome. Another possible 
explanation is the differences in permeability of the compound through the yeast cell 
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compared to the mammalian cell wall. Another limitation of using HIP-HOP is the 
restriction of identifying only protein targets due to their reliance on gene effect 
observations, so if indeed NITD770 targets something other than a protein, HIP-HOP 
would not be able to allow the identification of this target. 
 The effect of NITD770 on host cholesterol was investigated. It was speculated 
that the crude cell lysate, enriched with MVD, used for the preliminary MVD assay 
might contain other sterol biosynthesis enzymes that could be affected by NITD770. 
However, data showed that host total cholesterol levels and the cholesterol 
biosynthesis were unaffected, as shown by unaltered zymosterol levels, an 
intermediate product along the cholesterol biosynthesis pathway. 
 To identify the possible viral target of NITD770, resistant viruses were raised 
in the presence of this compound. By mapping the causal mutations raised from the 
NITD770-resistant viruses, three conserved mutations were identified within the NS5 
polymerase domain and this led to the investigation whether the viral polymerase is 
the target of this compound. Data showed that the triple mutations in NS5 resulted in 
an increase (approximately 1.7 times) in the polymerase activity compared to wild 
type protein. However, the IC50 values of NITD770 in the RdRp assay were high and 
similar in both the wild type (42 M) and the triple mutant protein (49 M). These 
high inhibitory concentrations suggested that NS5 polymerase activity is not a target 
of this compound and that the three conserved mutations within the NS5 are indirect 
resistant mutations, often referred to as compensating mutations. An example of such 
phenomenon is observed in the case of neuraminidase-resistant influenza viruses, 
which exhibit weaker binding hemagglutinins that enhance viral binding to host cells, 
rather than alter the effect on neuraminidase itself (Gubareva et al. 1998; McKimm-
Breschkin 2000). In this study, it was concluded that the mutations in the resistant 
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virus resulted in a viral polymerase that is more active in order to overcome the anti-
viral effect caused by the compound. 
 The possible interaction of NITD770 with NS5 was also studied by examining 
the effect of the compound on the intrinsic fluorescence property of NS5. It was 
observed that NITD770 quenches the NS5 protein‟s fluorescence (Annex-2). 
However, both the spectroscopy properties of NITD770 and the abundance of 
tryptophan residues in NS5 (ninety tryptophan residues) prevented a straightforward 
interpretation as to whether the interaction is specific. Our colleague, Dr Christian 
Noble, had recently attempted to co-crystallize the compound with NS5 without any 
success. Further studies needed to be performed, to this end, a multi-disciplinary 
effort, such as studying the kinetics of the association/disassociation of NITD770 with 
NS5 using isothermal calorimetry (ITC) or using surface plasma resonance (SPR) 
technology, is required to determine the specificity of this compound‟s interaction 
with NS5. 
 This study provided a more detailed characterization of the anti-viral profile of 
NITD770 in dengue infection. The inhibition of viral replication by this compound is 
shown not to be via its action on the RdRp activity and was concluded that the 
resulting resistant mutations were compensatory mutations. Colleagues (Wouter Schul 
and Andy Yip) in NITD tested NITD770 in mice model and found a 42% percent in 
reduction of viremia in mice after 3 days of treatment with 100mg/Kg twice daily oral 
dosing (data shown in Annex 3). Although the compound did reduce the viremia in 
this study, the effect was small in relation to the high dosage and long exposure used 
during the study. This further highlighted the need to determine the target of 
NITD770 to prevent any side effect that may arise from this compound. There are on-
98 
 




5. U18666A, A CHOLESTEROL TRANSPORT INHIBITOR AND ITS 
EFFECTS ON DENGUE VIRAL ENTRY AND REPLICATION 
5.1. INTRODUCTION 
 In drug research for anti-dengue therapy, compounds were designed to target 
viral proteins such as the viral envelope (during the entry/fusion step) (Costin et al. 
2010; Poh et al. 2009; Schmidt et al. 2010; Wang et al. 2009) and viral polymerase, 
NS5 (during the viral replication) (Latour et al. 2010; Niyomrattanakit et al. 2010; 
Yin et al. 2009). Alternative targets include host targets that have the advantage of 
reduced drug resistance faced by viral protein targeted drugs. For example, targeting 
host processes such as glucosidase (Chang et al. 2009; Liang et al. 2006), cholesterol 
modulation (Lee et al. 2008; Mackenzie et al. 2007; Rothwell et al. 2009) and host 
factors leading to the pathogenesis of DHF (Pastorino et al. 2010; Subramanya et al. 
2009). 
 Cholesterol is essential to various cellular structures and processes. It is 
required predominantly for the formation of cellular membranes (Cannon et al. 2006) 
and for the production of other important components, such as bile acid and steroid 
hormone synthesis. In a cell, the level of cholesterol is constantly regulated at three 
levels: during the intake of extracellular cholesterol in the form of light density 
lipoprotein (LDL) via endocytosis; during de-novo biosynthesis of cholesterol (Brown 
and Goldstein 1983) and during the efflux of cholesterol by ABCA1, a transporter 
found associated in the cell periphery (Higgins 1992). Viruses have been shown to 
affect cholesterol levels during infection (Syed et al. 2009) and when cholesterol is 
reduced in host cells, viral production is affected (Desplanques et al. ; Medigeshi et al. 
2008). Enzymes involved in the intermediate steps of biosynthesis, such as 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and mevalonate 
(diphospho) decarboxylase (MVD) were shown to be important in viral replication 
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(Sidorkiewicz et al. 2009). Statins, a widely known class of inhibitors that have been 
used to lower cholesterol levels in the treatment of cardiovascular diseases.  Inhibiting 
HMG-CoA reductase was also found to be effective against several viruses such as 
HIV, influenza virus and HCV (Bader et al. 2008; Kruger et al. 2006; Oh and Hegele 
2007). These findings highlight the possibility that modulating host cholesterol may 
inhibit dengue infection. 
 In this study, a cholesterol transport inhibitor drug, U18666A (3-β-[2-
(diethylamino)ethoxy]androst-5-en-17-one) (Liscum and Faust 1989) was used as a 
tool to allow us to study the role of cholesterol during DENV infection. Time-point-
of-addition experiment done in cells infected with DENV showed that U18666A 
reduces viral production at multiple steps of the infection. Subsequent studies showed 
that this compound inhibits viral trafficking and replication. The combined treatment 
of C75, a fatty acid synthase inhibitor and U18666A was also shown to have an 





5.2.1. Anti-viral activity of U18666A, a cholesterol transport inhibitor and its 
effect during viral infection 
 The compound, U18666A affects cholesterol levels in cells mainly via two 
mechanisms, the transportation of cholesterol in the endocytosis of host cells and the 
inhibition of oxidosqualene cyclase, an intermediate enzyme in the sterol 
biosynthesis. We observed that cholesterol is ubiquitously distributed in host cells 
(Fig. 5-1A; Control: FILIPIN III). When these cells were treated with U18666A for 
16 hours, it resulted in an accumulation of cholesterol in the late endosome (Fig. 5-
1A; U18666A: Co-labeled). This treatment resulted in significant reduction in viral 
production with more than 1 log of viral production observed at 16h pre-treatment and 
after entry (Fig. 5-1B; VIRAL PRODUCTION). The effect of this cholesterol 
transport inhibitor was even more pronounced when presented throughout the 
infection, as shown with a 3-Log reduction in viral production. Although the 1 hour 
entry did not cause as much viral reduction compared to 16 hour pre-treatment, it 
could be due to insufficient perturbation of host cholesterol homeostasis to see a 
pronounced effect on viral infection. The cell viability experiment was done in 
parallel with the anti-viral experiment and showed that U18666A‟s anti-viral effect 
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Figure 5-1: Antiviral effect of U18666A on dengue viruses. (A) BHK21 cells were 
treated either with (i) 0.9% DMSO (control) or (ii) 6 M of U18666A for 16 hours 
before fixation and labeled with either FILIPIN III (blue) or Lamp-1 (red). A co-
labeling was performed for U18666A treated cells. (B) Time-point-of-additions: 
BHK21 was treated with U18666A at 3 g/mL at various time-points during the 
course of infection by dengue viruses at MOI of 1. Viral supernatants were 
harvested 48 hours post infection and plaque assay was used to determine the viral 
titer. Cell viability was determined using CellTiter
®
 Glo assay kit  
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5.2.2. The importance of cholesterol in viral trafficking in cells 
  To study the early event of infection, immuno-fluorescence 
microscopy was used to examine viral binding on host cells and trafficking event of 
the endocytosed viruses. For virus binding experiments, viruses with a MOI of 50 
were added onto chilled BHK21 cells and incubated on ice for an hour. These virus 
bound cells were then fixed for immuno-labeling with anti-E antibody to visualize the 
viruses. In cold condition, viruses are able to bind to the cell surface but are unable to 
undergo endocytosis (Helenius et al. 1980). This experiment showed that viruses were 













Figure 5-2: Characterization of the effect of U18666A on the viral 
binding. (A) For cell binding study: Dengue viruses were added to 
BHK21 treated either with (i) 0.9% DMSO as control or (ii)16h 
pre-treatment with U18666A (3 g/mL). This was incubated on ice 
for one hour to allow the viruses to bind onto the cell surface. The 
cells were then washed and fixed, followed by immuno-labeling 
with anti-Env antibody (4G2) (Green) to visualize the bound 
viruses. DAPI (Blue) was used as a counter-stain for cell nuclei. 
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 In order to study the post-attachment event, infected cells were fixed at 
different timepoints over a time course of 24 hours post infection. Fixed cells were 
subsequently immuno-labeled with anti-E antibody to monitor the endocytosed viral 
particles. One hour post infection, viruses were observed in the cytoplasm of the host 
cells (Fig 5-3, Control 1h). Fusion of the viral particles was believed to have taken 
place before the time-point of 4 hours post infection as the endocytosed viruses could 
no longer be detected (Fig.5-3, Control 4h). Newly synthesized viral proteins were 
detected at the time-point of 12 hours post infection, with the labeling of E protein 
localized in the peri-nuclear regions of the host cells (Fig. 5-3, Control 12h). 
However, in cells where the cholesterol transport was arrested by U18666A, many 
endocytosed viral particles could still be labeled with the anti-E antibody (Fig 5-3, 
U18666A 4h). There was also less labeling of the newly synthesized viral protein at 
the time-point of 12h post infection (Fig. 5-3, U18666A 12h). Further investigation 
showed that these trapped endocytosed viruses were not found in the early endosomes 
(immuno-labeled with anti-EEA1 antibody; Fig. 5-4i), but found mainly in the late 
endosomes (immuno-labeled with anti-Lamp-1 antibody; Fig. 5-4ii). This resulted in a 
reduced level of infection as evidenced in the 12h and 24h time points, with reduced 


























Figure 5-3: The effects of U18666A on viral trafficking. The control and U18666A-
treated BHK21 cells were infected with dengue viruses (MOI of 50) and at various 
time-points of infections (1h, 4h, 8h, 12h and 24h), followed by fixing of these cells 
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Figure 5-4: Association of trapped viruses in Lamp-1 labeled compartments. BHK21 
cells were infected (moi of 50) and treated with U18666A (6 M) for 4h and then 
fixed and immuno-labeled with anti-Env antibody (4G2) (Green) and with either (i) 
anti-EEA1 antibody (Red) or (ii) anti-Lamp-1 antibody (Red). DAPI (Blue) was used 
as a counterstain for cell nuclei. 
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5.2.3. The importance of cholesterol in the replication of dengue viruses 
 Two in-house stablly transfected replicon cell lines (DENV replicon in A549 
cell line and DENV replicon in Huh7 cell line), carrying a reporter gene fused to the 
non-structural genes of DENV, were used to study the effect of U18666A on viral 
replication (Ng et al., 2007). This assay focused on the replication event, isolating this 
event from viral entry, trafficking and post replication. A range of concentrations of 
U18666A (0 to 100 M) were added to the replicon cell line for 48 hours. The treated 
replicon cell line was then assayed for the luciferase activity of the replicons. 
U18666A showed an inhibitory effect on the replicon activity, with a half maximal 
effective concentration (EC50) of 6.2 M in dengue replicon A549 cell line (Fig. 5-
5A) and 2.9 M in dengue replicon Huh7 cell line (Fig. 5-5B).  
5.2.4. Modulation of host cholesterol and zymosterol levels by U18666A. 
 The cholesterol level in host cells was measured using gas phase 
chromatography mass spectrometry (GC-MS). Quantification of lipids using GC-MS 
was performed by Dr Guanghou Shui. The total cholesterol was found to be slightly 
increased in infected cells (MOI of 1) treated with U18666A (48 hours treatment) 
(Fig. 5-6A). Zymosterol, an intermediate product of the sterol biosynthesis pathway, 
was measured using GC-MS, to monitor the de-novo biosynthesis of cholesterol in 
host cells. The data showed that zymosterol level was significantly reduced (p-
value=1.15E-06) in infected cells treated with U18666A (Fig.5-6B), indicating a 






























A         Dengue Replicon in A549 cell line  
B        Dengue Replicon in Huh7 cell line  
 




































Figure 5-5: Inhibition of viral replication by U18666A. A stably transfected dengue 
replicon in (A) A549 (B) Huh7 cell lines were used. These cells were treated with a 
concentration range of U18666A for 48h. The activity of replicons was measured 
via luciferase activity using Enduren
TM
 live cell substrate. The replicon cells were 
then lysed and quantified using CellTiter
®
 Glo assay kit for cell cyto-toxicity. Both 
the replication and viability activity is expressed as a percentage with the untreated 
















































































































A         Total Cholesterol Quantification 
B                Zymosterol  Quantification 
Figure 5-6: Quantification of cholesterol and zymosterol level. BHK21 cells 
were treated with either 0.9% DMSO as control or 6 M U18666A, then 
infected with dengue viruses (moi of 1) for 48h before lipids were extracted and 
quantified using GC-MS. Both (A) cholesterol and (B) zymosterol levels were 
normalised with total cell protein and expressed as a ratio of cholesterol / 
protein ( g/mL). T-test (unpaired unequal variances) was performed to compare 






5.2.5. U18666A has no effect on the association of viral proteins with lipid rafts 
and the formation of viral induced membranous structure 
 The effect of suppressed cholesterol biosynthesis (induced by U18666A as 
observed in figure 5-6B) on the viral replication machinery was investigated using 
both biochemical and ultra-structural approaches.  
 DENV‟s non structural proteins had been shown by Lee and colleagues to be 
associated with lipid rafts isolated from infected cells (Lee et al. 2008). Their lipid raft 
isolation protocol was used in this study with infected cells treated with U18666A to 
find out if reduced cholesterol transport and biosynthesis caused by U18666A would 
disrupt the association of the viral proteins with lipid rafts. The isolation of detergent 
resistant membrane (DRM) fraction, enriched for lipid rafts, was performed by DRM 
extraction with 1% Triton on ice, followed by using a sucrose-density gradient 
ultracentrifuge protocol (see Chapter 2, methods and materials). There was no noted 
difference, in the association of NS3 or NS4B with lipid rafts in the caveolin-rich 
fractions, between the control and U18666A- treated cells (Fig. 5-7).  
 In the ultra-structural studies, transmission electron microscopy (TEM) was 
used to observe dengue viral replication. The formation of viral induced membranous 
structures in both dengue replicon BHK21 cell line (Fig. 5-8A) and live virus 
infections (Fig.5-8B) were examined. It was observed that viral induced membranous 








































Figure 5-7: Association of viral proteins with lipid rafts. BHK21 cells were 
treated with either 0.9% DMSO as control or 6 M U18666A and infected with 
dengue viruses (MOI of 10) for 24h and then harvested for lipid raft extraction in 
1% triton on ice. The detergent resistant fractions were separated from the 
soluble fractions by sucrose density gradient. Fractions 2 to 4 represented the 
lighter density fractions collected from the top of the tube and fraction 5 to 10 
represented fractions collected from the bottom half of the tubes. Non-structural 
proteins, NS3 and NS4B, were immuno-blotted for and caveolin-1 was used as a 














Figure 5-8: Ultra-structural study of viral induced membranous structures. 
(A)Stably transfected dengue replicons in BHK21 cells were treated with either 
0.9% DMSO, control or 6 m U18666A for 24h before fixation for transmission 
electron microscopy (TEM). (B) For live virus infection, BHK21 cells (control) or 
U18666A treated cells, were infected with a MOI of 10 for 24 hours before 
fixation for TEM sample processing.  
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5.2.6. Effect of various intermediate sterol inhibitors on dengue replication  
 A set of sterol inhibitors were screened for anti-viral activity in both dengue 
replicon and HCV replicon cell lines (Table. 5-1). This experiment was based on a 
recent study (Owens et al. 2010) indicating that targeting the intermediate steps of the 
sterol pathway using commercially available sterol inhibitors can affect HCV 
replication. In the case of dengue replication, only U18666A exhibits anti-viral 
activity within the non-toxic concentration range, while other sterol inhibitors were 
either not effective or exhibited very narrow selective index (with CC50/EC50 values 
less than 4). Contrary to dengue replication, HCV replication was affected by most of 
the inhibitors save SR-12813 and R0 48-8071. It was also noted that U18666A had a 










Table 5-1: Effect of sterol inhibitors on DENV and HCV replicon cell lines. A class 
of sterol inhibitors targeting various intermediate pathways of sterol biosynthesis was 
tested in both dengue replicon-Huh7 cell line and HCV replicons-Huh7 cell line. The 
efficiency concentration ( M) to bring down 50% replication (EC50) and cyto-toxicity 
concentration ( M) for 50% killing (CC50) were tabulated in the table. The selective 




DENV Replicon HCV Replicon 
 
EC50 CC50 CC50/EC50 EC50 CC50 CC50/EC50 
Sterol inhibitors             
U18666A 2.8 34 12.1 <0.2 33.9 >30 
SR 12813 20.2 29.5 0.7 24.1 34.1 0.7 
Simvastatin 32.9 73.5 2.2 12.4 82.3 6.6 
Squalestatin No inhibition Increased replication 
Clomiphene 5.8 13.9 2.4 2.4 22.4 9.3 
R0 48-8071 4.1 9.5 2.3 7.1 14.9 2.1 
Triparanol 3.7 11.1 3 3.7 14.6 3.9 
AY-9944 7.8 15.9 2 3.6 20.4 6.7 
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5.2.7. C75, a fatty acid synthase inhibitor, has an additive anti-viral effect when 
used in combination with U18666A 
 Recent reports on the importance of lipid droplets (Samsa et al. 2009) and 
fatty acids (Heaton et al. 2010) in dengue infection both showed anti-viral activity of 
C75, a fatty acid synthase inhibitor. Figure 5-9 showed that C75 has anti-viral activity 
in dengue replicon-Huh7 cell line with an EC50 of 2.3 M and a CC50 value greater 
than 100 M. 
 These results prompted further investigation to perform a drug synergy 
experiment with C75 and U18666A and find out whether C75 can lead to an enhanced 
anti-viral activity with U18666A in the replicon cell line system. An ordered 
combination of both compounds, of varying concentrations, was set up in dengue 
replicon cells based on MacSynergy II format that relies on a mathematical model 
using the Bliss Independence theory (Prichard and Shipman 1990). This experiment 
allows the assessment of whether the anti-viral effect for the combination of C75 and 
U18666A is synergistic, additive or antagonistic. A series of eight replicates were 
calculated to be statistically significant at 95% confidence level. The strength of 
synergy between the C75 and U18666A were determined by looking at the volume 
under the curve whereby synergy volume of <25 M
2 
unit % is additive or non-
synergy, 25-50 M
2 
unit %  is minor but significant synergy, 50-100 M
2 
unit % is 
moderate synergy and >100 M
2 
unit % is strong synergy. A synergy volume value of 
12 M
2 
unit % was calculated at 95% confidence interval for the two compounds 
(Fig. 5-10A), indicating that these two compounds acted in an overall additive 
manner. The three dimensional synergy plot, illustrated in figure 5-10B, showing low 
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Figure 5-9: Inhibition of viral replication by C75, a fatty acid synthase inhibitor.  
Stably transfected dengue replicon in Huh7 cell lines were used. These cells were 
treated with a concentration range of C75 for 48h. The activity of replicons was 
measured via luciferase activity using Enduren
TM
 live cell substrate. The replicon 
cells were then lysed and quantified using CellTiter
®
 Glo assay kit for cell cyto-
toxicity. Both replication activity and viability were expressed in percentage with 
















   
SYNERGY PLOT 
(95%) 
  C75 
uM
       25 0 0 0 -1 0 -1 
 8.33 0 4 1 1 0 0 
 2.78 0 0 0 0 0 0 
 0.93 0 3 1 1 1 0 
 0.31 0 0 0 0 0 0 
 0 0 0 0 0 0 0 
 
 




Figure 5-10: A detailed calculation of combined dose effect of U18666A and C75 
in inhibition of dengue replication using MacSynergy II. A five point dilution of 
U18666A was tested in matrix combination format with C75 to obtain the synergy 
calculation. (A) A table showing the synergy calculation and the total synergy 
value calculated was 12. (B) A three dimensional synergy plot with 95% 
confidence interval was used to illustrate non-synergy between the two drugs as 




 Previous studies on the role of cholesterol in flaviviruses predominantly used 
statins to inhibit sterol synthesis in host cells and methyl-beta-cyclo-dextrin (MBCD) 
to extract cholesterol from cell plasma membrane. U18666A was used in this study 
because it has been shown to act on host cholesterol via two main pathways: (i) by 
blocking the transport of endocytosed cholesterol in the form LDL, resulting in an 
accumulation of cholesterol in the late endosome and (ii) by suppressing the 
intermediate steps of the de-novo sterol biosynthesis via oxidosqualene cyclase 
(Sexton et al. 1983). This study aimed to find out whether disrupting these two 
processes in cholesterol homeostasis would have an impact on DENV infection.  
 Plaque assay data indicated that the early event of infection is affected by 
U18666A. The virus binding experiment indicated that cholesterol does not play a 
role in virus binding onto the host cell, which is in consistent with earlier studies by 
others (Reyes-Del Valle et al. 2005) using MBCD. These studies showed that viruses 
were still able to bind to cells from which plasma membrane cholesterol had been 
extracted by the cholesterol compound.  
 This study showed that dengue virus infection depends on host cholesterol in a 
post-attachment manner, i.e. during viral trafficking in host. The arrestment of the 
endocytosed viruses in the late endosomes of treated cells (4 hours into infection) 
resulted in a severe reduction of newly synthesized viral proteins at the later time-
points of 12 hours and 24 hours post infection. This might be due to the high level of 
accumulated cholesterol in the late endosomes caused by U186666A, which created a 
perturbance in the cholesterol level in these trafficking vesicles, for efficient viral 
fusion to occur. Hence, cholesterol homeostasis is important in the trafficking of 
DENV for successful infection. 
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 Furthermore, in this study, it was demonstrated that DENV replication is 
reliant on its host de-novo cholesterol biosynthesis. An anti-viral effect in infected 
cells was observed when level of zymosterol (an intermediate product of synthesized 
cholesterol) in host cells was suppressed by U18666A.  
Earlier work done by others on the characterization of cholesterol levels in ER 
membranes in U18666A-treated cells showed a 40% reduction in cholesterol in these 
treated cells (Lange et al. 1999). Hence, one question asked in this study is whether 
reduction in the cholesterol levels in E.R, caused by U18666A, would affect the viral 
replication machinery, believed to be located on membranous structure derived from 
E.R. However, it was observed that U18666A treatment did not disrupt the 
association of viral proteins, NS3 and NS4B, with lipid rafts isolated from infected 
cells. Ultra-structural study using TEM also showed that the viral induced membranes 
were still formed under the effect of U18666A in the DENV infected cells in 24h post 
infection.  
 An attempt to find a more potent cholesterol biosynthesis suppressing 
compound than U18666A was also tried. A list of various commercially available 
sterol inhibitors was tested in the dengue replicon cell line. The result from this study 
argues against any potential use of these inhibitors for anti-dengue therapy due to the 
toxicity observed. This prompted further investigation to find out whether other lipids 
played a role in the replication event. Fatty acids have recently been shown to be 
important to dengue replication (Heaton et al. 2010). A fatty acid synthase inhibitor, 
C75, was tested on dengue replicon assay and was found to be effective against 
dengue replication. C75 gave an overall additive suppression on dengue replication 
when used in combination with U18666A. This implies that both cholesterol and fatty 
acids are important for successful dengue infection. 
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6. SUMMARIZING CONCLUSION AND FUTURE OUTLOOK 
6.1. TARGETING VIRAL FUSION VIA THE OG POCKET NEAR TO 
THE HINGE REGION OF DENV E PROTEIN 
 Targeting viral entry via inhibition of membrane fusion is attractive for 
antiviral strategy because it is inhibitory at the early step of infection. With the 
elucidation of the dengue envelope (E) protein structure (both pre-and post-fusion 
structures), there is information available for a structure activity relationship (SAR) 
approach to design small molecules inhibitors. In Chapter 3, a rational approach using 
in-silico selection of predicted E-binders was used to look for dengue virus fusion 
inhibitor. Faced with a lack of suitable fusion assay that would allow the monitoring 
of fusion-inhibition in a high throughput manner, an assay based on cell-cell fusion in 
mosquito cell line was set up. This assay was used for compound screening in a 96 
wells format. This assay is relatively easy to set up once the parameters (such as cell 
seeding density, viral titer for infection, and pH value for fusion) are optimized. It 
does not require the need of molecular cloning of reporter genes, unlike reported cell-
cell fusion assay for HCV which is based on reporter system (Kobayashi et al. 2006). 
A similar fusion assay based on cell-cell fusion was also adopted by Kampmann and 
colleagues to validate the fusion inhibitors they had identified from the in-silico 
screening of E binders (Kampmann et al. 2006). They used a mixture of anti-prM and 
anti-E antibodies to visualize infected mosquito cells and then count for cell-cell 
fusion event by looking for fluorescently tagged mutli-nucleated cells. 
To date, there are several published studies (see in table 1.1 page 23) using 
OG binding pocket as the defined ligand for an in-silico search for small molecules 
that bind and block dengue viral fusion. These reported fusion inhibitors are 
structurally distinct. As mentioned in chapter 3, the trifluoro-phenyl motif of 
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NITD448 (predicted to be buried into the hydrophobic OG pocket) shares some 
similarity to the chloro-phenyl-thiophene tail of compound 6 reported by our 
colleague in NITD (Wang et al. 2009). Two teams identified inhibitors that shared the 
common feature of a central thiazole ring in their most active compounds (Kampmann 
et al. 2009; Li et al. 2008). Another team reported fusion compounds which are 
tetracycline derivatives (Yang et al. 2007). However, none of the reported inhibitors, 
including NITD449, made it to the clinical studies. This raised a question on the 
validity of using OG-binding pocket as a target for rational drug design.  
The molecular properties of how antiviral compounds enter and bind onto a 
hydrophobic pocket are unknown and experimentally difficult to be determined. A 
compound‟s ability to enter and bind can be attributed to the compound‟s structural 
flexibility and also the compound‟s interaction with the residues found within the 
pocket of the protein. Often in drug discovery, a co-crystallization of the compound 
with the target can provide hints to the binding interaction of the compound. Such 
structural information would greatly aid in the validation and future design of better 
generation of fusion inhibitors. This is hampered by the current protocol for the 
expression and purification of DENV E protein that is unable to yield large amount of 
E protein required for structural studies. Only one team managed to show the binding 
of the inhibitor they identified (PO2) with the DENV E protein using preliminary 
NMR spectrometry studies. Much effort and improvement in physical interaction 
studies are required in order for SAR improvements in these reported fusion 
inhibitors. 
The discovery of OG binding pocket is only a starting point for small 
molecular fusion inhibitor research. With the increasing knowledge learnt about the 
dynamics of E protein during the different stages of viral fusion, it would be 
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worthwhile to explore these transition stages as alternative target site beside the OG 
pocket. Such alternative sites as proposed by Yennamalli and colleagues could be a 
cavity that is either present in the dimer but not in the trimer (blocking trimerization) 
or cavity that is present in the dimer interface (blocking transition to post-fusion state) 
(Yennamalli et al. 2009). 
6.2. NITD770, AN ANTI-VIRAL SMALL MOLECULE WITH UNKNOWN 
MECHANISM OF ACTION 
 Determining how a compound acts on the targeted disease is an important 
factor in the development of clinical drugs. Understanding the way in which a 
compound interacts with its target can help chemists design a second-generation of 
compounds with improved potency. Structural studies, such as X-ray crystallography, 
are often used to study compound binding site. This facilitates a rational improvement 
on the molecular properties of the compound, which can result in a higher affinity to 
the target and thereby potentially resulting in increased potency of the compound. The 
other positive highlight of identifying the mechanism of action of the compound is to 
eliminate possible biological side effects. Many clinical candidates did not progress to 
the market due to the unexpected side effects exhibited by the compound. Hence, 
knowing which biological pathway(s) is/are being affected by the compound, one can 
make a Go or No-go decision in further drug development. This decision is also based 
on the predicted toxicity to the patient at an earlier phase of the drug discovery 
progress. These factors potentially save time and money on failed outcomes of 
clinical candidates. 
 In Chapter 4, a small molecule mevalonate pyrophosphate decarboxylase 
(MVD) inhibitor (NITD770) was found to have a good potency with a selective index 
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of EC50/CC50 of more than 100 and specificity towards the members of the 
flaviviridae family. Target validation of this compound revealed that it was not 
targeting MVD. Various approaches involving cross-disciplinary studies were done 
without any success to explain the anti-dengue activity exhibited by this compound. 
There is an on-going effort to decipher the mode of action for NITD770. Although it 
was observed in this study to have no effect on the lipid raft or cholesterol 
metabolism, a more thorough lipid profiling, looking into other species of lipids in 
treated cells, may provide insight and perhaps answer the question as to whether host 
lipid is a target of this compound. In the quest to find NITD770‟s target, it would be 
useful if a fluorescent probe could be tagged on to NITD770 to visualize, by 
microscopy, the entry and localization of this compound into host cell in order to aid 
prediction of site of action. An affinity pull-down of host cell materials would also be 
an alternative approach to look for interacting host targets. Both techniques require 
some form of chemical manipulation to attach a linker to the small molecule, and this 
was found to compromise NITD770‟s bioactivity. A new technique used for target 
identification, known as Drug Affinity Responsive Target Stability (DARTS), which 
does not require any modification to the drug to be investigated (Lomenick et al. 
2009) could potentially be used. This technique is based on the conferred stabilization 
of targeted proteins by the compound upon binding. Stability of the bound proteins 
can be caused by either induced conformation stability or masking of the protease 
recognition sites present in the proteins. Hence, the compound bound proteins, among 
the pool of protein mixtures in a cell lysate, become resistant to protease treatment, 
which can then be identified using mass spectrometry. This could be applicable for 
future work in finding the target of NITD770. 
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6.3. THE DEPENDENCE OF HOST CHOLESTEROL BY DENGUE VIRUS 
AND TARGETING HOST LIPID METABOLISM AS AN ANTI-VIRAL 
STRATEGY 
 Caution is needed when dealing with host factors as a target class for anti-
dengue therapy because potential harmful effects to human may occur. However, 
there is still a therapeutic window to work with if the drug exhibits greater potency 
against the viral target than it does against the host homologue. There have been an 
increasing number of findings pointing towards the importance of perturbation of host 
lipid metabolism (as discussed in the introductory chapter of this thesis). The work 
done in Chapter 5 allows us to gain insight into the dependence of DENV on host 
cholesterol homeostasis.  
Targeting lipid in viral entry 
This study described that the level of cholesterol in the late endosome of host 
endocytosis pathway is important for efficient trafficking of DENV for successful 
infection. This could be due to a reduction in the fluidity of the host endosome 
membrane (caused by the U18666A induced accumulation of cholesterol, a saturating 
lipid) resulting in hampering of fusion with the viruses. It is generally believed that 
different viruses fuse with the host trafficking vesicles based on the pH threshold 
value of its E protein (pH threshold value was determined using liposome based 
fusion assay) for triggering viral fusion (White and Helenius 1980). In the field of 
DENV research, scientists are unable to explain the observation of viral fusion 
occurring in late endosome even though early endosome has an acidic content 
sufficient to trigger viral fusion in-vitro. This question could perhaps be answered by 
the recent study done by Zaitseva‟s team proposing that dengue virus engineers it own 
lipid bilayer to contain late endosome enriched lipid, bis(monoacylglycero)phosphate, 
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for its timely fusion at this compartment (Zaitseva et al. 2010). This further 
strengthens the point that targeting host lipid important for viral fusion can result in an 
anti-viral activity. Targeting host lipid can also provide an alternative or complement 
strategy to targeting the viral E protein for designing a fusion inhibitor of dengue 
virus.    
Targeting lipid in viral replication 
Host membrane lipids and proteins could serve as scaffolds for the assembly 
of viral replication complex. They can also mediate the targeting of the viral 
replication proteins to the site for replication. Based on immuno-labeling studies and 
ultra-structural studies, we now know that viral replication takes place in close 
association with the membranous structure near to the proximity of the host 
endoplasmic reticulum. Several (+) RNA viruses have been observed to induce 
membranous proliferation (Bienz et al. 1992; Egger et al. 2002; Salonen et al. 2005). 
Membrane-bound viral cytoplasmic replication is not restricted to RNA viruses, DNA 
virus such as poxvirus, also replicates in the cytoplasm (Schramm and Locker 2005). 
Hence, there is a consensus that these viruses depend on the host lipids for 
establishment of viral replication in host. Several plus-strand viruses remodel their 
host membranes to create structures, known as spherules that may serve to 
concentrate the viral replication proteins for efficient replication. These induced 
membranous structures may even act as a shelter from the harmful cellular proteases 
and nucleases, during the synthesis of new viral genetic material. Mackenzie and 
colleagues did some pioneering work in flavivirus, West Nile virus (WNV), where 
they observed the redistribution of the host cholesterol in the plasma membrane to the 
site of viral replication during infection (Mackenzie et al. 2007). Of recent year, 
dengue viral protein NS3 was shown to recruit fatty acid to the site of replication by 
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targeting fatty acid synthase (FASN) to the viral factory and possibly also responsible 
for stimulating the biosynthesis of this lipid needed for efficient viral replication 
(Heaton et al. 2010).  
 Limiting the de-novo synthesis of host cholesterol level is also explored in 
anti-viral therapy. This approach is encouraged by the fact that there are commonly 
used cholesterol-lowering drugs (statins) taken by patients for treating other diseases, 
emphasizing the possibility of developing a cholesterol anti-dengue drug that is safe 
to humans. In chapter 5, the study showed that dengue viral replication is severely 
suppressed when the de-novo synthesis of a sterol intermediate was inhibited (shown 
by reduced zymosterol levels) by U18666A. Subsequent investigation was done to 
determine whether other intermediate steps in the sterol biosynthesis can be targeted 
using pharmacological intervention in the dengue replicon screening assay. The 
results showed that, besides U18666A, the remaining compounds were either 
ineffective or had narrow selective index to avoid host toxicity. Interestingly, in 
parallel screening using HCV replicons, several sterol inhibitors were found to be 
suppressing HCV replicons at lower concentration within the non-toxicity 
concentration. This data implies that HCV is more dependent on host cholesterol 
biosynthesis compared to DENV. HCV has been the focus of intense drug discovery 
for the last two decades. Many findings previously found in HCV are currently being 
tested in anti-dengue research. One needs to note that the disease caused by HCV is 
different from DENV, with HCV causing a chronic infection whereas DENV causes 
an acute infection. This may explains the difference observed in the potency of the 
sterol inhibitors between these two viruses. Hence, it would be interesting for future 
studies to compare the efficacy of these sterol inhibitors in other viruses which cause 
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either chronic infection or acute infection. This may help to gain insights into the 
mechanism of viral establishment in relation to host cholesterol modulation.  
Targeting host fatty acid metabolism remains an unexplored territory in anti-
dengue therapy. As mentioned earlier in this section, with the recent finding of 
regulation of fatty acid by the dengue viral protein, NS3 (Heaton et al. 2010), this 
metabolic pathway could be investigated in more detail as a host target for an anti-
dengue drug. The studies reported in chapter 5 place emphasis on the fact that viral 




6.4. TARGETING VIRAL AND HOST FACTORS IN ANTI-DENGUE 
DRUG DISCOVERY 
 In summary, the work reported in this thesis explored the possibility of 
targeting two processes, the viral fusion event (targeting E protein) and the host 
cholesterol metabolism, in the search for compounds that inhibit dengue infection.  
Using a rational approach to look for an entry-inhibitor drug has the advantage of 
specificity to viral target. It also accelerates the hit-to-lead progression in drug 
discovery pipeline, by reducing the chance of biological side effects and aiding SAR 
improvement for secondary compounds. In the case of designing a cholesterol-
targeted drug in anti-dengue treatment, it is important that the drug has a well defined 
mechanism of action with specificity towards the targeted protein or process, due to 
the possible cross toxicity to host. In my studies, there were similar encounters with 
narrow therapeutic range for most of the cholesterol compounds targeting the various 
intermediate steps in host cholesterol biosynthesis. In order to overcome the host 
toxicity, more studies are necessary to fine-tune the balance between anti-viral 
activity and host toxicity. Cholesterol is an essential component of many cellular 
processes in host cell and hence, this may be the reason of the limited therapeutic 
range observed when targeting the host cholesterol metabolism in dengue infection. 
Perhaps, it would be more successful for an anti-dengue compound if the lipid target 
is required for a unique function found in the pathogen, compared to the ubiquitous 
cholesterol. Identification of such lipid will require studies involving detail lipid 
profiling of the dengue virus particles or infected host cells. 
The paradigm of anti-viral drugs has been to achieve a high anti-viral effect 
and low host toxicity. Targeting a viral protein reduces the chance of cross-inhibition 
of host protein but it is often only effective against one type of virus and encounters 
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the problem of the emergence of resistant viruses. It is an arduous journey to develop 
a drug from bench to patients. Hence, having a drug that has broad-spectrum activity 
seems a worthwhile effort to be pursued by scientists. With the increasing reports on 
studies using genome scale analysis on the host-pathogen interactions, it seems 
promising that these studies could lead to the identification of unique host processes 
as potential targets for inhibiting viral infection in future. 
 Another issue to consider when developing anti-dengue drug is the 
pathogenesis of this disease, with the likelihood to progress from the milder case of 
DF to the more severe case of DHF/DSS where the host immune responses are 
perturbed. In the latter case, anti-dengue drugs that modulate the host response would 
be a more effective approach to treat these patients. 
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ANNEX 1: CLONING OF DENGUE 4 NS5 MUTANT PROTEINS 
 Total RNA was extracted from tissue culture media supernatant containing 
D4MY01-22713 virus using the QIAamp Viral RNA kit (Qiagen, USA) following the 
manufacturer‟s instructions. The purified RNA was then reverse-transcribed with 
Superscript III (Invitrogen, USA) using the primer 5′-CAATGGTCTCTTTGGTGT 
TTG-3′. After reverse transcription, the primers 5′-CATATGGCTAGCGGAACTGG 
GACCACAGGA-3′ and 5′-GCGGCCGCTTACAGAACTCCTTCACTCTC3′ were 
used to amplify NS5. The amplified PCR band was subsequently cloned into a zero 
blunt TOPO PCR cloning vector. After verification of the DNA sequence, the TOPO 
vector was cut with NheI and NotI restriction enzymes to release the DENV-4 NS5 
fragment and cloned into pET28a cut with the same enzymes. The ligation reaction 
was transformed into Top10 cells (Invitrogen, USA). 
 The single mutants were made using appropriate primers together with the 
wild-type DNA template. The double mutants were created with appropriate primers 
and single mutant as template and the triple mutant were created using appropriate 
primers and double mutant as template as listed in the tables below. 
Primers  Nucleotide sequence 
8171S    5‟-gacgacacagtaggctgggacacgagaatc  -3‟ 
8172A 5‟-gtcccagcctactgtgtcgtcagcatatat  -3‟ 
8173S 5‟-gtgggaacatacgctttaaacacattcactaac  -3‟ 
8174A 5‟-tgtgtttaaagcgtatgttcccacctgtccact  -3‟ 
8175S 5‟-actaacatgggagttcaactcatccgccaa  -3‟ 




Mutants PCR TEMPLATE Primers 
pET28a D4 NS5FL A535V  pET28a D4NS5FL 8171S and 
8172A 
pET28a D4 NS5FL G607A pET28a D4NS5FL 8173S and 
8174A 
pET28a D4 NS5FL E615G pET28a D4NS5FL 8175S and 
8176A 
pET28a D4 NS5FL AG535/607VA   pET28a D4 NS5FL A535V 8173S and 
8174A 
pET28a D4 NS5FL AE535/615VG pET28a D4 NS5FL A535V 8175S and 
8176A 
pET28a D4 NS5FL GE607/615AG pET28a D4 NS5FL G607A 8175S and 
8176A 
pET28a D4 NS5FL 
AGE535/607/615VAE   
pET28a D4 NS5FL 
AG535/607VA   
8175S and 
8176A 
Annex 1: Primers Sequence 
 The PCR reaction was carried in 50 L of reaction volume consisting of 50 ng 
of template (pET28a D4 NS5 FL or mutants), 200 M of dNTP mix, 1 M of primers 
and 1 L of pfu polymerase (Stratagene, USA). This PCR reaction was performed at 
94
0
C for 2 minutes, followed by 16 cycles of 94 
0
C for 30 seconds, 55
0
C for 30 
seconds and 68
0
C for 16 minutes. A final extension step was carried out for 10 
minutes at 72
0
C. DpnI restriction enzyme (1 L) was used to digest away the input 
DNA template at °C for 1 hour. After the digestion, the resulting PCR product was 
transformed into top10 bacteria cells. Colonies were picked and the presence of 
mutation was verified with direct sequencing.  
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ANNEX 2: QUENCHING OF INTRINSIC FLUORESCENCE OF NS5 BY 
NITD770 
NITD770 vs NITD419

























Annex 2. Quenching of NS5 intrinsic fluorescence by NITD770. Specific 
fluorescence emission was measured at a wavelength of 350nm. Normalized 
fluorescence (F/F0 where F0 is the fluorescence without compound) was then plotted 
against increasing concentrations of compound. Two sets of experiments were set up 
to test the specificity of NITD770 effect on NS5. (A) NITD770 versus NITD419 (an 






















Annex 3. An evaluation of NITD770 efficacy in a dengue viremia model in mice 
AG129 mice (with knockout interferon  receptor and interferon  receptor) 
purchased from B&K Universal were injected intraperitoneally with 0.4 mL of RPMI-
1640 medium containing 5000,000 PFU/mL of DENV-2 (TSV01). The infected mice 
were then dosed with either NTD770 or vehicle (100% corn oil) by s.c injection. 
Various concentration of NITD770 was tested in TSV01-infected AG129 mice for 
three days followed by the determination of the viremia load in these mice using 












ANNEX 4: CHIKUNGUNIA VIRUS CPE ASSAY 
BHK21 cells were seeded, one day before, at a cell density of 20,000 cells/well 
(RPMI-1640 containing 2% FBS) in a 96 well plate. On the following day, the cells 
were infected with 200 L of 10,000 PFU/mL chikungunya viruses. NITD770 was 
then added and incubated for 2 days treatment before viral titer determination using 
plaque assay.  
 
 
